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Tuberculosis (TB) is the leading killer globally owing to an infectious disease. There is 
consequently an urgent need to develop novel TB drugs and shorter regimens to treat the 
causative agent, Mycobacterium tuberculosis, an imperative which demands the identification 
of new drug targets in essential mycobacterial pathways. To that end, the work presented in 
this dissertation aimed to functionally characterize ribF, an essential gene in the 
mycobacterial riboflavin (RF; vitamin B2) biosynthetic pathway. Given the role of RF as a 
core component of the essential flavin cofactors, flavin mononucleotide (FMN) and flavin 
adenine dinucleotide (FAD), it was hypothesized that silencing ribF would disrupt the 
biosynthesis of all flavoproteins, crippling numerous (essential) processes within the 
organism. Moreover, based on previous observations in Bacillus subtilis, it was predicted that 
the mycobacterial ribF homolog might play a role in regulating the  rib operon (comprising a 
cluster of RF pathway genes) – either directly by binding to the FMN riboswitch, or 
indirectly through the production of FMN from RF, in turn enabling riboswitch-mediated 
repression of downstream genes.  
CRISPR interference (CRISPRi) technology was used to generate an anhydrotetracycline 
(ATc)-inducible ribF hypomorph of M. smegmatis, a widely exploited mycobacterial model. 
Consistent with other organisms, ribF was shown to be essential for in vitro growth of M. 
smegmatis: CRISPRi-mediated depletion of ribF was bacteriostatic, resulting in a 10-fold 
growth inhibition in liquid media and corresponding to no reduction (0 log-fold change) in 
colony forming units (CFU). Moreover, targeted metabolomic analyses revealed that ribF 
depletion was associated with accumulation of 6,7-Dimethylribityllumazine (DMRL), 
suggesting that the disruption of RibF function blocked conversion of RF to the essential co-
factors, FMN and FAD, in turn inhibiting cell growth. Notably, the lethality of ribF depletion 
could not be complemented chemically by exogenous supplementation of growth media with 
RF, FMN or FAD. Downregulation of ribF also caused enhanced susceptibility to the known 
cell wall-targeting agent, vancomycin, but not to the putative RibF domain inhibitor, 
thonzonium bromide, suggesting an alternative mechanism of action or impaired bacillary 
permeation. In summary, these data support the inferred essentiality of ribF in mycobacteria, 
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Tuberculosis (TB) is an ancient disease, evidence of which has been identified in Egyptian 
mummies dating as far back as 2500 BC, yet it continues to plague mankind (Zink et al. 
2007). Its causal agent was first described by Robert Koch in 1882 as the “tubercle bacillus” 
(Sakula 1983) and subsequently named Mycobacterium tuberculosis (Mtb) in 1886 (Grange 
1982). According to the World Health Organization, more than  301 000 new TB cases were 
reported in South Africa alone in 2018, while the incidence of co-infection with HIV was 
estimated to be approximately 177 000 cases (WHO 2019). Despite the availability of 
effective drug regimens, TB remains the number one killer globally owing to an infectious 
disease: an estimated 21 000 deaths were reported in SA, whereas mortality as a result of co-
infection with HIV escalated this to more than 42 000 deaths (WHO 2019). Hence, TB is 
considered an “opportunistic infection”, commonly afflicting those with HIV or 
immunosuppressive ailments (Holmes et al. 2003; Fenner et al. 2013).  
Mycobacterium bovis Bacille Calmette-Guérin (BCG) is the only vaccine against TB, 
but its protective efficacy is limited to infants and wanes as individuals approach adolescence 
(Mangtani et al. 2014). Moreover, a negative effect of BCG use has been observed in HIV-
positive infants and severely immunodeficient individuals in whom vaccination can lead to 
disseminated BCG infection and adverse complications, thus posing an enormous threat to 
patients residing in high HIV-TB disease prevalent countries (Hesseling et al. 2007). While 
administration of the BCG vaccine has been shown to provide effective partial immunity 
against TB in animal models, it does not afford a complete clearance of infection (Hinchey 
2007). Notably, very recent work suggests that shifting from intradermal to intravenous 
delivery can dramatically improve efficacy, though this result is still to be validated in 
humans (Darrah et al. 2020). As administered currently, the effect of the vaccine remains 
inconsistent and ranges from 0-80% depending on the geographical region and local TB 




Modern anti-TB drug therapy, which has proven to be very effective in treating 
patients with drug-susceptible Mtb infection, began with the introduction  of streptomycin  
and para-aminosalicylic acid dual therapy in the 1940s (Figure 1.1) (Feldman et al. 1945; 
Lehmann 1946; Mitchison and Davies 2012). The currently recommended TB regimen 
comprises a phased multidrug combination, beginning with an intensive phase of rifampicin 
(RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutol (EMB) (Figure 1.1) for a period 
of two months (Luciani et al. 2009). Subsequently, an extended “continuation phase” 
comprising treatment with RIF and INH is utilized to eradicate any remaining bacilli. These 
drugs are given to patients who have never been on anti-TB treatment before or have been on 
treatment for less than a month and are considered “new patients”, presumably carrying drug-
susceptible Mtb (WHO 2010).  
 
Figure 1.1: Diverse molecular structures of efficacious first line anti-TB drugs used to treat Mtb 
(adapted from PubChem Sketcher V2.4). 
However, the major challenge with modern drug therapies is the emergence of drug 
resistance, and TB disease is no exception with 11 000 new MDR/ rifampicin resistance (RR) 




categories: mono-resistance, which describes resistance to any single first-line drug;  
multidrug resistance (MDR-TB) is classified as Mtb infection that does not show 
susceptibility to INH and RIF; and extensively drug resistant (XDR) Mtb, defined as MDR 
plus resistance to any fluoroquinolone in conjunction with one of the three second line 
injectables: amikacin, capreomycin or kanamycin (WHO 2014b, 2006). In addition, a newly 
described TB drug resistance has been identified as RR which describes resistance to RIF 
either as mono- or poly-resistance i.e., MDR or XDR (WHO 2016b). Notably, the newly 
approved anti-TB drugs, bedaqualine and delamanid, have been licensed for the treatment of 
both MDR- and XDR-TB (Gler et al. 2012; Cohen 2013). However, both drugs must be used 
for a standardized period of 24 weeks and are restricted to patients with no other therapeutic 
options (WHO 2014a).  
Bedaquiline is a diarylquinoline (R207910), the first drug in a novel class approved 
for TB treatment since the approval of rifampicin in 1971 (Avorn 2013). Diarylquinolines are 
considered similar to quinolones but do not inhibit DNA gyrase, instead targeting the 
essential, membrane-bound mycobacterial adenosine triphosphate (ATP) synthase, thus 
interfering with energy production and intracellular metabolism (Andries, Verhasselt, 
Guillemont, Gohlmann, et al. 2005). Delamanid, previously known as OPC-67683, was 
derived from the class of nitro-dihydro-imidazooxale compounds which potently inhibit 
mycolic acid synthesis, an essential component of the mycobacterial cell wall (Matsumoto et 
al. 2006). Despite compelling evidence that both drugs are potent in targeting specific 
enzymes from different metabolic pathways, there still exists a need to identify novel drug 
target candidates within other essential pathways since separate resistances to these drugs 
have already been detected in patients (Somoskovi et al. 2015; Hartkoorn, Uplekar, and Cole 
2014). To that end, the project detailed here was motivated by the need to identify new 
metabolic targets in essential mycobacterial pathways; specifically, with the aim of 
elucidating the function and putative essentiality of RibF, a predicted enzyme in the 
biosynthesis of riboflavin, precursor of the flavin cofactors, flavin mononucleotide (FMN) 








1.2 The riboflavin biosynthetic pathway (RBP) 
Riboflavin (RF; also known as vitamin B2) is an essential biochemical component in the 
cellular metabolic functioning of all life forms and was the third vitamin to be discovered 
after thiamine (Northrop-Clewes and Thurnham 2012). RF, which comprises an isoalloxazine 
ring structure linked to a ribityl ring chain at the N10 position (Edwards 2014) (Beztsinna et 
al. 2016), is a precursor of FMN and FAD, both of which serve as cofactors for multiple 
metabolic enzymes (Figure 1.2). Notably, vertebrates do not have the ability to synthesize 
RF and must obtain the vitamin from their diets whilst many plants, fungi and 




Figure 1.2: Schematic of the RibF-catalyzed conversion of RF to FAD via an FMN intermediate  








In Mycobacterium smegmatis (Msm), it is postulated that RF is generated by two 
pathways: through purine metabolism, and via the pentose phosphate route. The enzymes 
pyrimidine deaminase/reductase (encoded by ribD; MSMEG_3067), α-subunit RF synthase 
(encoded by ribE; MSMEG_3071), GTP cyclohydrolase (encoded by ribAB; 
MSMEG_3072), 3,4-dihydroxy 2- butanone 4- phosphate (3,4-DHBP) synthase (also 
encoded by ribAB; MSMEG_3072) and β-riboflavin synthase subunit (ribH; MSMEG_3073) 
produce one RF molecule from a single molecule of guanosine-5-triphosphate (GTP) and two 
ribulose-5-phosphate molecules (Figure 1.3). The genomic context of all RF related genes is 
provided in Supplementary figure S2. The Mtb homologs of all RF genes and their 
functional annotations are listed in Supplementary table 1. RF on its own has limited 
functions and needs to be transformed into its derivatives, the biologically active flavins to 
fulfil its major role as a source of flavin cofactors. In the cell, RF undergoes a biochemical 
reaction with flavokinase, an enzyme that utilizes adenine triphosphate (ATP) to generate 
FMN. Most flavoenzymes require FAD as a cofactor; therefore FAD synthetase must further 
transform FMN to FAD by attachment of AMP to the pre-phosphorylated FMN molecule, 
















Figure 1.3A: Predicted RF biosynthetic pathway in Msm. The schematic is inferred from the known B. subtilis 
pathway. Pathways are indicated by coloured circles and enzymes responsible for the indicated 
biotransformations are indicated in rectangles. The enzymes in orange represent Mtb homologs of the proposed 
Msm genes (green) in the pathway and immune activating ligands (discussed later) are represented by blue 
rectangles. RibF, the enzyme which serves as the focus of this project, is highlighted in red rectangles. Note that 
genetic nomenclature differs across the model bacteria: the bifunctional pyrimidine deaminase/ reductase 
enzyme (ribG) and α-subunit of riboflavin synthase (ribB) in B. subtilis are named ribD and ribE, respectively, 
in E. coli. Furthermore, separate genes, ribB and ribA, code for 3, 4-DHBP synthase and GTP cyclohydrolase, 
respectively in E. coli whereas the same functions are performed by a single ribA-encoded enzyme in B. subtilis 
(adapted from NCBI Pubmed Biosystems pathway). 
 
Figure 1.3B: Genomic context of the proposed rib genes in Msm. Green highlighted genes represent those that 
participate directly in the RF biosynthetic pathway while non-green highlighted genes located on the left are 
upstream while those downstream are located on the right of the proposed RBP genes. The putative rib operon 










1.3 The regulation of RF biosynthesis  
The RF biosynthetic pathway has not been studied in detail in mycobacteria; therefore, the 
pathways presented here are based on those elucidated in the model organisms, E. coli and B. 
subtilis.  
 
Figure 1.4: Annotation of ribF homologs in various microorganisms including model bacteria in which the RF 
biosynthetic pathway is most studied. (Mycobacterium species and model bacteria homologs adapted from 
Mycobrowser [https://mycobrowser.epfl.ch/] and Genolist [[http://genolist.pasteur.fr/] databases respectively).  
In B. subtilis, the production of RF is controlled by two regulators, RibC and RibR 
(Supplementary figure S4). RibC is a bifunctional flavokinase/ FAD synthase, similar to 
mycobacterial RibF (Supplementary figure S3) (Mack, van Loon, and Hohmann 1998a), 
while RibR encodes a monofunctional flavokinase involved in regulating the rib operon (RF 
biosynthetic gene operon) (Solovieva et al. 1999). The inactivation of either gene leads to RF 
accumulation (Azevedo et al. 1993). In B. subtilis, the genes ribDG-E-AB-H constitute a 
solitary transcriptional unit, the expression of which is controlled by a FMN riboswitch 
















Figure 1.5: Structure of a typical riboswitch. The aptamer domain (green) carries the ligand binding site and the 
expression platform (brown) adopts a structural conformational change dependent on  binding of the effector 
molecule (pink) which will lead to transcriptional termination or either translational impotence (Garst, Edwards, 
and Batey 2011). 
Bacterial riboswitches are localised in the untranslated region (UTR) of mRNAs that 
have the capability to bind to natural ligands to regulate the expression of downstream genes 
(Winkler, Cohen-Chalamish, and Breaker 2002a; Mironov et al. 2002b; Mellin and Cossart 
2015; Winkler and Breaker 2005). Structurally, riboswitches possess two functionally distinct 
segments; an aptamer region containing the ligand binding domain and a regulatory 
expression platform to regulate downstream genes (Mellin and Cossart 2015; Winkler and 
Breaker 2005). Mechanistically, upon cognate ligand-aptamer region binding, a 
conformational alteration is induced in the expression platform to regulate gene expression 
either through transcriptional attenuation or sequestration of the ribosomal binding site, 
thereby inhibiting translation (Winkler, Cohen-Chalamish, and Breaker 2002a; Mironov et al. 
2002a). 
This “ribDG FMN riboswitch” is embedded in the 5’ untranslated region of the 
bacterial mRNA and can efficiently control gene expression through alterations in its 




(Mironov et al. 2002a; Winkler, Cohen-Chalamish, and Breaker 2002a; Winkler and Breaker 
2005). A second FMN riboswitch is located in the 5’ UTR of ribU (ypaA) (Vogl et al. 2007) 
which codes for a putative RF transporter (Kreneva et al. 2000).  
Thus, upon binding of FMN to the riboswitch, ribU translation initiation is impeded 
through a mechanism involving ribosomal binding site sequestration (Winkler, Cohen-
Chalamish, and Breaker 2002a). RibR in B. subtilis can act as a positive regulator to 
overcome repression mediated by the FMN riboswitch, thereby allowing rib gene expression 
under excessive intracellular concentrations of the cofactor FMN by directly interacting with 
the aptamer region of the riboswitch (Higashitsuji et al. 2007). It is believed that bacteria 
have evolved this regulatory mechanism to cope with increased levels of FMN when sulphur 
metabolism is taking place due to co-expression of ribR and sulphur compound uptake and 
degradation factors (Pedrolli, Kuhm, et al. 2015). 
Iron levels can also affect the expression of the RF pathway in certain bacteria, likely 
due to the importance of the flavin cofactors in iron metabolism. In the methanotrophic 
Methylocytis species, flavin secretion levels are increased under iron depletion 
(Balasubramanian, Levinson, and Rosenzweig 2010). Similarly, the rib operon of 
Caulobacter crescentus, an aquatic bacterium, shows upregulated expression when subjected 
to iron limiting conditions. Furthermore, mutations in the ferric uptake repressor, fur, have 
been shown to induce rib transcript overexpression and a putative fur binding site was 
identified in the upstream region of the rib operon in this species (da Silva Neto, Lourenco, 
and Marques 2013).  
1.4 Inhibiting FMN riboswitch function  
Streptomyces davawensis JCM 4913 (Otani et al. 1974) and S. cinnabarinus (Jankowitsch et 
al. 2012) both synthesize roseoflavin (RoF), an antibiotic structurally similar to RF. This 
natural chemical analogue is converted to the non-functional cofactor analogues, roseoflavin 
mononucleotide (RoFMN) and roseoflavin adenine dinucleotide (RoFAD), respectively, via 
the RibF enzyme domains, flavokinase and FAD synthetase. The mode of action of RoFMN 
involves binding and downregulating the genes controlled by the FMN riboswitch and has 
been observed in Listeria monocytogenes, S. coelicolor and B. subtilis (Lee, Blount, and 
Breaker 2009; Mansjo and Johansson 2011; Ott et al. 2009). When E.coli is exposed to RoF, 
the modified flavins get incorporated into flavoproteins, either adversely affecting their 




Walsh et al. 1978). However, in humans (Pedrolli et al. 2011), B. subtilis (Grill et al. 2008), 
Streptomyces coelicolor and S. davawensis (Pedrolli et al. 2012), the same biochemical 
reaction is carried out by RibC, a RibF homolog. The biosynthesis of RoF in S. davawensis is 
achieved by three enzymes: first, 8-demethyl-8-aminoriboflavin-5’-phosphate synthase 
(RosB) converts FMN to 8-demethyl-8-aminoriboflavin mononucleotide (AFMN), an 
essential RoF intermediate (Schwarz et al. 2016). Next, an unidentified phosphatase catalyses 
the reaction that converts AFMN to 8-demethyl-8-aminoriboflavin (AF) and, finally, RoF is 
produced as a result of catalysing AF and S-adenosylmethionine by N,N-8-demethyl-8-
aminoriboflavin dimethyltransferase (RosA) (Jankowitsch et al. 2011; Tongsook et al. 2016).   
Also, ribB-M-A-H and ribG have been shown to be responsible for the synthesis of 
RF in S. davawensis and S. coelicolor and encode enzymes similar to the B. subtilis genes 
ribG-B-A-H that catalyse this synthesis (Grill et al. 2007). Moreover, ribM encodes a 
riboflavin permease which plays a role in importing RoF into the cell (Hemberger et al. 
2011). There is also evidence suggesting that ribB-M-A-H might be regulated by an FMN 
riboswitch, based on sequence analysis of the upstream region (Grill et al. 2007). Binding of 
FMN to the aptamer region of the ribB FMN riboswitch is thought to inhibit translation 
initiation of the ribB-M-A-H mRNA (Vitreschak et al. 2002a) in contrast to transcription 
termination as observed for the ribG FMN riboswitch in B. subtilis (Winkler and Breaker 
2005; Mironov et al. 2002a).   
1.5 The role of flavoproteins in cellular processes 
Flavin cofactors are necessary for flavoprotein cellular redox reactions and it has been 
suggested that approximately 1-3% of genes code for flavoproteins in bacteria and eukaryotes 
(De Colibus and Mattevi 2006). These proteins are involved in abundant energetic reactions 
such as fat and carbohydrate metabolism, protein metabolism, oxidative stress, 
photosensitization, and vitamin activation of folate and pyridoxine (Ashoori and 
Saedisomeolia 2014; Beztsinna et al. 2016; Haase et al. 2014). Their crucial role in metabolic 
reactions owes to their unique ability to mediate reactions that involve transferring either one 
or two electrons (Edwards 2014). In addition, they have the capacity to facilitate redox 
processes such as DNA repair, circadian cycling, light sensing and fruit body development, 
reinforcing their essentiality in cellular functionality (Tagua et al. 2015; Takahashi 2015; Xu 
et al. 2015; Christie et al. 2015; Yang et al. 2016). Furthermore, flavins play a role in 




dimethyl sulphide (DMS) as a source of sulphur under light emitting conditions. These 
bacteria secrete photosensitizers, FAD and RF, which undergo catalytic reactions that 
photooxidize DMS to dimethyl sulphoxide. The presence of FAD induces 
methanesulphonate, formate, formaldehyde and sulphate production which this organism uses 
as a sulphur source (Hirano et al. 2003).   
It has been theorized that the intestinal pathogen Campylobacter jejuni can increase 
bioavailable iron by extracellular insoluble ferric iron reduction (Fe
3+
) into soluble ferrous 
iron (Fe
2+
); the synthesis of RF intensifies this reductive activity (Crossley et al. 2007). It has 
also been recognized that RF secreted by Acidobacteria geothrix fermentans can act as a 
secondary electron shuttle which plays a role in approximately 20-30% of electron transfer 
activities under reduced iron conditions (Mehta-Kolte and Bond 2012). RF secreted by 
Shewanella sp. reduces Fe
3+ 
oxides (von Canstein et al. 2008) by directly mediating electron 
transfer to an electron acceptor electrode (Marsili et al. 2008). Furthermore, the flavin 
electron shuttle serves as the main extracellular electron transfer system either through direct 
contact or via nanowires with FAD secretion mediated by the FAD exporter enzyme, Bfe 
(Kotloski and Gralnick 2013). In addition, recent work illustrated the ability of alkaphilic 
bacterial consortia to utilize extracellular Fe
3+
 as a distinct electron acceptor under anaerobic 
respiration where the rate at which Fe
2+
 produced is dependent on the quantity of 
extracellular RF (Fuller et al. 2014). Surprisingly, the Gram-positive bacterium, 
Desulphotomaculum reducens, has the ability to secrete RF, utilizing this as an electron 
shuttle in the presence of pyruvate; this occurs through the solid-phase as hydrous ferric 
oxide gets reduced. However, in these conditions, bacterial growth is modulated by pyruvate 
fermentation rather than Fe
3+ 
respiration, with iron reduction used to dispose of reducing 
equivalents (Dalla Vecchia et al. 2014).  
Apart from RF derivatives, other molecules such as deazaflavins are responsible for 
mediating a broad range of redox reactions with the aid of flavin-dependent enzymes in an 
array of biological systems (Hemmerich, Nagelschneider, and Veeger 1970; Walsh 1980). 
FMN and FAD are therefore widely used cofactors that play an integral part in metabolic 
reactions across three domains of life; bacteria, archaea and eukarya. However, relatively few 
organisms have the ability to synthesize and utilize 5-deazaflavins (O'Brien, Weinstock, and 
Cheng 1967; O'Brien, Weinslock, and Cheng 1970). These compounds are structurally 
similar to flavins whereby the carbon atom acts as a substitute for the N5 atom of the 




specifically, 7,8-didemethyl-8-hydroxy-5-deazaflavin (F0) and its lactyl oligoglutamate 
phosphodiester derivative (F420) (Cheeseman, Toms-Wood, and Wolfe 1972; Eirich, Vogels, 
and Wolfe 1978). Generally, the role of F420 in bacteria is not fully understood but has been 
experimentally shown to be synthesized in a single bacterial phylum: the Actinobacteria 
(Saviola and Bishai 2006) which includes the genus, Mycobacterium. Phenotypic and 
biochemical studies have shown evidence of F420 synthesis as well as metabolic function and 
reduction by all members of the Mycobacterial genus including saprophytes, i.e., Msm, M. 
fortuitum, the opportunistic pathogens, M. avium and M. kansasii, and the human pathogens, 
Mtb Complex and M. leprae (Lin and White 1986; Bair, Isabelle, and Daniels 2001; 
Purwantini, Gillis, and Daniels 1997).  
Despite massive genome decay (Cole et al. 2001), the observation that M. leprae is 
capable of synthesizing F420 supports an evolutionarily conserved role in mycobacterial 
metabolism. As opposed to methanogens, F420 is not considered essential for optimal growth 
of mycobacteria under standard conditions in vitro: the F420 biosynthetic gene, fbiC, and the 
F420-dependent glucose-6-phoshphate dehydrogenase, fgd – implicated in the mechanism of 
action of (and resistance to) nitroimidazoles including pretomanid (Baptista et al. 2018) – 
have successfully been disabled in Msm (Taylor et al. 2010; Purwantini and Mukhopadhyay 
2009), Mtb (fgd1) (Gurumurthy et al. 2013; Manjunatha et al. 2006), and M. bovis (Choi, 
Kendrick, and Daniels 2002). However, a range of studies have shown that F420 is required 
under unfavourable conditions (Boshoff and Barry 3rd 2005). Mycobacterial strains unable to 
synthesize F420 are unfit to survive oxygen deprivation, oxidative stress, nitrosative stress or 
antibiotic treatment (Purwantini and Mukhopadhyay 2009; Gurumurthy et al. 2013; Hasan et 
al. 2010).  
Numerous enzymes have been annotated in mycobacteria which are functionally 
dependent on F420. The pathogenic Mtb codes for the F420-reducing hydroxymycolic acid 
dehydrogenase (fHMAD) which oxidizes hydroxymycolic acids to ketomycolic acids in the 
cell wall (Bashiri et al. 2012; Purwantini and Mukhopadhyay 2013). The mycolic acid 
derivatives participate in the integrity and permeability of the cell envelope causing them to 
be less susceptible to cytotoxic agents such as antibiotics (Yuan et al. 1998; Dubnau et al. 
2000; Sambandan et al. 2013). Furthermore, preliminary data indicate that the flavin/ 
deazaflavin oxidoreductase superfamily (FDOR-AAs) might also be involved in fatty acid 
modification, in contrast to other members of the FDOR-Bs superfamily which reduce the 




including biliverdin produced by host heme oxygenase-1 and mycobacterial HugZ in the 
carbon monoxide (CO) generating pathway and mycobilin produced mycobacterial MhuD in 
the CO bypass pathway (Kumar et al. 2008; Nambu et al. 2013; Contreras et al. 2014). 
1.6 Activation of mucosal-associated invariant T (MAIT) cells by microbial RF 
derivatives 
The host immune system functions to distinguish self from non-self, thus defending against 
any potential opportunistic invaders (Pancer and Cooper 2006). Very simply, it is divided 
into innate and adaptive immunity, which differ primarily in the defence mechanisms 
employed, their time dependence, and their capacity for memory (Janeway 2001), although 
recent studies elucidating “trained immunity” suggest a more complex interplay (Netea et al. 
2016). The innate response serves as the first line of defence since it utilizes the germline-
encoded receptors for pathogen recognition and is mostly non-specific. Interaction with these 
innate receptors induces classical responses such as apoptosis, cytokine release, degranulation 
and phagocytosis (Medzhitov and Janeway 2002). In contrast, the adaptive response is highly 





 T cells, which form part of the “delayed” adaptive immune response. Adaptive 
immunity is primarily based on recognition of foreign bodies by antigen-specific receptors 
expressed on B- or T-cell surfaces (Boehm and Bleul 2007). The adaptive response has 
classic features, as it relies on clonal expansion and is delayed by 4 to 7 days prior to adaptive 
response initiation (Janeway 2001). MAIT and invariant Natural killer T (iNKT) cells, 
referred to as “innate-like” T cells, are semi-invariant cells that recognize non-classical Major 
Histocompatibility Complex 1 (MHC 1) presenting antigens; that is, the CD1d molecule is 
recognized by iNKT cells (Kinjo et al. 2011) whereas non-classical MHC class 1, MR1, is 




 T cells 
that recognize MHC I and MHC II presenting antigens, respectively (Boehm and Bleul 
2007).  
MAIT cells are part of a healthy mucosal immune system and are essential in the 
control of bacteria in these tissue sites. They also have a high population density in the liver, 
colon lamina propria, lung and female genital tract; constituting approximately 20-40%, 1-
8%, and 10-20% of resident T cells in these locations, respectively (Tang et al. 2013; 
Sundstrom et al. 2015; Treiner et al. 2003; Le Bourhis et al. 2010; Gibbs et al. 2017). MR1-




and react to cells that express MR1 without possession of microbial ligands (Lepore et al. 
2017). MAIT cells are regarded as MR1T subsets that express a semi-invariant T-cell 
receptor composed of unique Vα 7.2-Jα33, Jα12 or Jα20 segment rearrangement and Vβ 
limited repertoire (Reantragoon et al. 2013; Lepore et al. 2014). Human MAIT cells are 
classified by their co-expression of the semi-invariant TCRwith an abundant expression of C-
type lectin CD161 and the α-subunit of the interleukin 18 receptor (IL-18R) and are highly 
dependent on the expression of promyelocytic leukemia zinc finger (PLZF) and retinoic acid-
related orphan receptor γt (RoRγt), an innate-like transcription factor that highlights their 
peculiar functions (Dusseaux et al. 2011; Martin et al. 2009; Le Bourhis et al. 2010). These 
cells are able to induce an innate-like immune response despite being T cells (Treiner et al. 
2003; Martin et al. 2009), allowing them to respond at high specificity without the time-lag 
experienced by the traditional adaptive response, preventing any further pathogen 
manifestations. 
MAIT cells recognize a specific group of microorganisms which includes Mtb, E. 
coli, Lactobacillus sp. and fungi such as Candida albicans, but viruses instead stimulate their 
activation in an MR1-independent manner. Upon induction, MAIT cells produce pro-
inflammatory cytokines – interferon-γ (IFNγ), tumour necrosis factor (TNF), IL-22 and IL-
17A and cytotoxic mediators such as granzyme B and perforin, as a response mechanism to 
potential infection (Gold et al. 2010). MAIT cells recognize a novel class of antigens; in 
particular, microbial RF-derived metabolites and degraded folic acid derivatives (Kjer-
Nielsen et al. 2012). Kjer-Nielsen and colleagues were the first to report 6-formylpterin (6-
FP) and 6-(rRL-6-CH2OH) as MR1 binding ligands (Kjer-Nielsen et al. 2012) which are 
products of folic acid degradation. Although crystallography data revealed that these products 
covalently bind to the Lys 43 of the MR1 groove, they do not induce MAIT cell activation 
(Kjer-Nielsen et al. 2012; Lopez-Sagaseta, Dulberger, Crooks, et al. 2013; Lopez-Sagaseta, 
Dulberger, McFedries, et al. 2013) but rather antagonize MR1T as a result of competing with 
other activating ligands (Harriff et al. 2016). More recently, novel bacterial MR1T ligands 
that have been identified include 7,8-didemethyl-8-hydroxy-5-deazariboflavin (F0), 
photolumazine I (PLI) and photolumazine III (PLIII), all secondary products of the RF 
pathway (Harriff et al. 2018). Also, mass spectrometry used to analyse cell supernatants from 
Salmonella typhimurium, identified rRL-6-CH2OH as a MR1 ligand. Importantly, rRL-6-
CH2OH is structurally similar to RF precursors and, as such, is considered a secondary 
metabolite that can robustly activate TRAV1-2
+




et al. 2012; Lopez-Sagaseta, Dulberger, Crooks, et al. 2013; Lopez-Sagaseta, Dulberger, 
McFedries, et al. 2013).  
Following the identification of 6-FP and rRl-6-CH2OH, a considerable number of 
MR1 ligands began to emerge. These include two pyrimidine single-ringed compounds, 5-(2-
oxopropylideneaminouracil)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-
oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU) (Figure 1.6), which are regarded as 
by-products of both bacteria and host cell glycolysis and have the capability to potently 
activate MAIT cells (Greene et al. 2017; Corbett et al. 2014). These molecules are products 
derived from the chemical reaction between the RF biosynthetic intermediate, lumazine 
precursor (5-amino-6-D-ribitylaminouracil; 5-A-RU) and methylglyoxal and glyoxal (Figure 






Figure 1.6: Schematic diagram of MAIT cell antigens generated from the RF pathway. Potent RF ligands 
capable of inducing MAIT cell activation are highlighted in blue rectangles: 7-Hydroxy-6-methyl-8-
ribityllumazine, 6,7-Dimethyl -8-ribityllumazine, 5-OE-RU and 5-OP-RU. 5-A-RU acts as a precursor that 
generates 5-OE-RU and 5-OP-RU as the result of a biochemical reaction with glyoxal and methylglyoxal, 
respectively. 
Accordingly, unstable lumazine compounds, 7-hydroxy-6-methyl-8-D-ribityllumazine 
and 6,7-dimetyl-8-D-ribityllumazine (Figure 1.6), have also proven to act as MR1 ligands 
which led to strong MAIT cell stimulation (Meermeier et al. 2016; Patel et al. 2013). Despite 
RF metabolites being the main metabolites to induce activation of MAIT cells, there is 
evidence that these cells can be activated by other ligands; for example, Meermeier et al. 
illustrated TRAV12-2
+
 MR1- restricted T cell recognition from a bacterial Streptococcus 
pyogenes strain which was incapable of synthesizing RF (Meermeier et al. 2016) but were not 







Figure 1.7: Schematic diagram of the MR1-dependent and MR1-independent cytokine-dependent MAIT cell 
activation pathways. (A) During bacterial infections, MAIT cells can be stimulated in a MHC class 1-related 
molecule (MR1)-dependent manner as a result of their T cell receptors recognizing the MR1-presented bacterial 
RF ligands; 7-Hydroxy-6-methyl-8-ribityllumazine, 6,7-Dimethyl -8-ribityllumazine, 5-OE-RU or 5-OP-RU. 
(B) Alternatively, the MR1-independent pathway could be activated and is primarily governed by inflammatory 
cytokines such as IL-18 and -12 produced by the infected APC which are sensed by MAIT cells via the 
cytokine-receptor interaction. As a result of MAIT cell activation, a cascade of immune responses is stimulated 
and ultimately suppresses viral replication or bacterial growth. APC, antigen presenting cell; CCL3-CC, 
chemokine ligand 3; GM-CSF, granulocyte-macrophage colony stimulating factor; IL-R, interleukin receptor; 
IFNᵧ, interferon gamma, TNF, tumour necrosis factor.   
MAIT cell activation is dependent on two pathways, either the MR1-dependent or the MR1-
independent pathway. According to the prevailing model, during bacterial infections, the 
invading pathogen is engulfed by an APC which is degraded by cell lysis. As the pathogen is 
disintegrated, the intracellular contents are made available to the APC along with selected RF 
metabolites (Figure 1.7) which are presented via the MR1 protein to the MAIT cell TCR to 
induce MAIT cell activation. Upon MAIT cell activation, various cellular responses will be 
activated such as cytotoxic responses, MAIT cell proliferation and infected cell lysis. 
Viruses and certain bacteria cannot synthesize RF, but have nevertheless been shown 
to be capable of robustly stimulating MAIT cells. This suggests that there is another pathway 
at play, termed the MR1-independent cytokine-dependent activation pathway. This pathway 
does not rely on RF metabolite derivatives but instead depends on cytokines released by the 
infected APC as a result of APC-pathogen intracellular lysis. Generally, MAIT cells express 
abundant levels of IL-18 and IL-12 which have surfaced as major cytokines that activate 
MAIT cells upon cytokine-receptor binding as a result of viral or bacterial infection (Chua et 
al. 2012; Meierovics, Yankelevich, and Cowley 2013; Jesteadt et al. 2018). In contrast, IL-18 
is not essential for MAIT cell IFNᵧ production during in vivo infection (Jesteadt et al. 2018). 
Of importance, deletion of the IL-12p40 subunit resulted in insufficient control of F. 
tularensis and M. bovis intracellular growth reflecting the importance of MAIT cells in 
restricting pathogen growth (Meierovics, Yankelevich, and Cowley 2013; Jesteadt et al. 
2018). However, in vitro studies have shown that, whether or not F. tularensis and 
Enterococcus faecalis produce RF, they are still able to evoke IFNᵧ production by MAIT 
cells in a cytokine dependent manner (Jesteadt et al. 2018; Ussher et al. 2014).  Furthermore, 
the examination of the MR1 binding pocket shows that known ligands do not have the 




2013), which suggests that more conformed diversified ligands can be presented by MR1 but 
have yet to be discovered.  
More recently, it was shown (Keller, Eckle, et al. 2017) that the MR1 pocket can 
present diverse chemical structures due to its high structural plasticity. Of note, several 
agonists have been identified: that is, diclofenac and the chemical inhibitors; 3-
formylsalisylic acid, 5-formylsalisylic and 2,4-diamino-6-formylpteridine. Complex binding 
of the TCR from MAIT cells in complex with MR1 protein bound to stimulants and non-
stimulants showed explicit ligand orientation and contacts within the MR1 binding pocket 
(Keller, Eckle, et al. 2017). The versatility of MR1 to capture diverse chemical structures 
capable of either MAIT cell activation or inhibition indicates the probability that certain 
drugs or drug-like molecules could regulate the normal functioning of MAIT cells in 
mammals. However, none of the endogenous mammalian ligands have been identified, 
although their existence is highly plausible. 
The role of MAIT cells in detecting bacterial pathogens represents a strong motivator 
for studying the RF pathway in mycobacteria: we proposed that the depletion of ribF, the 
gene of interest in this study, should lead to an accumulation of a RF precursor which could 
act either as a MAIT cell activator or antagonist,  (Azevedo et al. 1993), the implication of 
which requires further investigation (Harriff et al. 2018).  To this end, the recently described 
CRISPR interference (CRISPRi) technique (Rock et al. 2017) was selected as the preferred 
method to downregulate the expression of ribF in mycobacteria.   
1.7 Transcriptional repression using CRISPR interference (CRISPRi) 
CRISPRi is a tool derived from the ability of some bacteria to specifically cleave foreign 
DNA in order to restrict pathogen survival (Makarova et al. 2011). This naturally occurring 
“bacterial immunity” pathway has been manipulated in CRISPRi to block the transcription of 
specified gene targets and is now widely employed as a tool to mediate the downregulation of 
essential genes or to knockout non-essential genes (Janssen 2018). This system requires three 
major components: a single deactivated CRISPR-associated protein-9 endonuclease, dCas9, 
and two short RNAs, CRISPR RNA (crRNA) and a trans-activating crRNA (transcrRNA) 
which is partially complementary. 
These two RNAs combine to form a single guide RNA (sgRNA) comprising ~20 




determined by the protospacer adjacent motif (PAM) sequence, 5’-NNAGAA-3’, and 
Watson-Crick base pairing of the sgRNA to the target DNA (Wright, Nunez, and Doudna 
2016; Horvath et al. 2008; Deveau et al. 2008). To induce transcriptional repression and 
prevent cleavage of the target region (i.e., to enable transcriptional inhibition via steric 
hindrance rather than gene editing), the Cas9 protein activity has been deactivated (dCas9) 
through targeted point mutations within the HNH (H840A) and RuvC (D10A) nuclease 
domains (Qi et al. 2013a; Bikard et al. 2013). On expression, dCas9 binds to the target 
sequence forming a dCas9Sth (this enzyme originates from Streptococcus thermophilus) - 
sgRNA complex which efficiently represses the gene of interest, ensuring complete 







Figure 1.8: CRISPRi prevents transcription of the target gene. The sgRNA made up of the target region (red) 
and dCas9 handle (green) directs the dCas9 enzyme to the sequence of interest causing obstruction of the RNA 
polymerase (RNAP; purple) (adapted and modified from Rock et al. 2017). 
Notably, the production of dCas9Sth-sgRNA is under the control of an inducible 
anhydrotetracycline (ATc) promoter hence to initiate gene knockdown cells are exposed to 
ATc. Additionally, the sgRNA is also regulated by a separate inducible ATc promoter. The 
sgRNAs can be specific for either one of the template strands when targeting the promoter, 
but obstruction of transcription by targeting the non-template strand notably produces up to 




proved to be more successful in E. coli and B. subtilis, reducing gene expression by a 
thousand-fold, whereas testing in mycobacteria yielded poor results, producing just four-fold 
knockdown of gene expression (Choudhary et al. 2015; Singh et al. 2016), and was 
associated with toxic effects (Nielsen and Voigt 2014).  
The S. pyogenes Cas9 is most commonly used in genomic engineering based on its 
ability to produce DNA double stranded breaks to sequences that are adjacent to -NGG- PAM 
sequences (Doudna and Charpentier 2014; Sontheimer and Barrangou 2015; Terns and Terns 
2014). However, pioneering work by Jeremy Rock and Sarah Fortune and colleagues (Rock 
et al. 2017) involving the testing of codon optimized dCas9 proteins from either the type IIA 
or type IIC subfamilies identified dCas9Sth1 as optimal for mycobacterial use. This system 
has subsequently been validated in our laboratory in generating large-scale Msm knockdown 
libraries (de Wet et al. 2018) and was used here to inducibly inhibit ribF transcription. 
1.8 Rationale and hypothesis 
The overall aim of this study was to assess the function of ribF in Msm, a fast growing and 
non-pathogenic mycobacterial model organism (Shiloh and Champion 2010). RibF is 
annotated as encoding a bifunctional protein responsible for the generation of the flavins, 
FMN and FAD. It was hypothesized, therefore, that this enzyme plays a role in regulating the 
rib operon either directly or indirectly by influencing the riboswitch, precedent for which 
exists in B. subtilis where ribR has been shown to overpass repression withheld by the FMN 
riboswitch (Mack, van Loon, and Hohmann 1998a; Solovieva et al. 1999; Lee et al. 2001).  
Given the role of this predicted essential enzyme (DeJesus et al. 2017; Sassetti, Boyd, and 
Rubin 2003a; Griffin et al. 2011a) in the operation of numerous flavoproteins which require 
cofactors for their functioning, it was expected that depletion of ribF would cripple numerous 
critical processes within the mycobacterial cell, validating RibF as a potential drug target.  
1.9 List of objectives 
The specific objectives for this proposed study were therefore: 
i) To knock down the expression of ribF in Msm by inducible CRISPRi. 
ii) To measure the efficacy of each sgRNA in the ribF knockdown mutants. 





iv) To determine the minimal inhibitory concentration of ATc sufficient to induce the 
same inhibitory effect as the commonly used 100 ng/ml ATc standard. 
v) To investigate whether depletion of RibF was bacteriostatic or bactericidal. 
vi) To quantify the ribF transcript levels in the knockdown strain to verify transcriptional 
depletion in this system. 
vii) To determine if the ribF hypomorph could be rescued by substrates: RF, FMN or 
FAD. 
viii) To determine whether the depletion of RibF increased susceptibility to specific anti-
mycobacterial agents and proposed FAD synthetase inhibitors. 
ix) To investigate the influence of RibF depletion on the expression of the rib operon. 
x) To investigate the consequence of ribF depletion on various metabolites of the RF 
biosynthetic pathway; namely ribulose-5-phosphate, 6,7-dimethyl-8-ribityllumazine 










































2.1 Materials and methods 
2.1.1 Bacterial strains, plasmids and growth conditions 
To create hypomorphs (targeted gene knockdown mutants), single guide RNAs (sgRNAs) 
comprising short oligonucleotides of ~ 21 bases were synthesized and cloned into the 
pLJR962 vector backbone (Rock et al. 2017) for transformation into E. coli and subsequently 
electroporated into Msm for targeted gene repression, the details of which are outlined below. 
All E. coli and M. smegmatis (Msm) strains used in this study are derivatives of DH5α 
and mc
2
155 respectively (Table 2.1) and were kept at -80ºC in 35% (v/v) glycerol for 
storage. All Msm strains were grown in Middlebrook 7H9 (Difco
TM
) supplemented with 
0.02% (v/v) glycerol, 10% (v/v) Middlebrook Oleic Acid Dextrose Catalase (OADC) 
enrichment (Difco
TM
), 0.02% (v/v) of 25% Tween80 and 25 µg/ml kanamycin (Kan) where 
appropriate. In liquid culture, the strains were grown in 50 ml Erlenmeyer flasks at 37ºC in a 
shaking incubator (IncoShake incubator, Labotec). In contrast, on solid media, strains were 
grown on Middlebrook 7H10 agar supplemented with 0.05% (v/v) glycerol and 10% (v/v) 
OADC containing 25 µg/ml Kan where appropriate, incubated in a 37ºC stationary incubator 
(IncoCool incubator, Labotec). 
All E. coli strains used for propagating vectors were grown in Luria-Bertani (LB); 
0.5% (v/v) yeast extract, 1% (v/v) tryptone and 0.5% (v/v) NaCl  broth containing 50 µg/ml 
Kan and grown overnight at 37ºC in a shaking incubator. Transformants were plated onto 
Luria-Bertani agar (LA) and incubated overnight at 37ºC in a stationary incubator. 
 
Table 2.1: List of bacterial strains used in this study 




recA1 endA1 gyrA96 thi-1 
relA1 
Promega 




MSM_WT High frequency 
transformation mutant of 
Msm ATCC 706 
Snapper et al., 1990 
CRISPR vector Strain carrying CRISPRi vector 
backbone pLJR962  
This study 
MSM_RibF1   CRISPRi ribF1 knockdown 
strain 
This study 
MSM_RibF2  CRISPRi ribF2 knockdown 
strain 
This study 
MSM_RibF3  CRISPRi ribF3 knockdown 
strain 
This study 
MSM_RibF4   CRISPRi ribF4 knockdown 
strain 
This study 
MSM_RibF5   CRISPRi ribF5 knockdown 
strain 
This study 
MSM_RibF6   CRISPRi ribF6 knockdown 
strain 
This study 
MSM_RibF7   CRISPRi ribF7 knockdown 
strain 
This study 
MSM_RibF8    CRISPRi ribF8 knockdown 
strain 
This study 
MSM_RibF9   CRISPRi ribF9 knockdown 
strain 
This study 
MSM_RibF10  CRISPRi ribF10 knockdown 
strain 
This study 







2.1.2 Plasmids used in this study  
The list of sgRNA constructs generated is tabulated below and their respective sequences are 
shown in Table 3.1   
Table 2.2: List of plasmids used this study 
Plasmid Composition References 
pLJR962 Anhydrotetracycline inducible 
Tet
R
 expressing Sth1 and dCas9, 




Rock et al., 2017 
pLJR962_ribF1 ribF knockdown construct 
created by insertion of sgRNA1 
oligo  
This study 
pLJR962_ribF2 ribF knockdown construct 
created by insertion of sgRNA2 
oligo 
This study 
pLJR962_ribF3 ribF knockdown construct 
created by insertion of sgRNA3 
oligo 
This study 
pLJR962_ribF4 ribF knockdown construct 
created by insertion of sgRNA4 
oligo 
This study 
pLJR962_ribF5 ribF knockdown construct 
created by insertion of sgRNA5 
oligo 
This study 
pLJR962_ribF6 ribF knockdown construct 
created by insertion of sgRNA6 
oligo 
This study 
pLJR962_ribF7 ribF knockdown construct 







2.1.3 DNA extraction 
2.1.3.1 Mini-prep plasmid DNA isolation 
Purified plasmid was isolated according to instructions of the Zyppy plasmid miniprep kit 
(ZYMO RESEARCH). Positive E. coli transformants harbouring desired plasmids were 
allowed to grow overnight at 37ºC and cells were centrifuged at 4000 rpm for 5 minutes 
(min) (Allegra
TM
 X-22R Centrifuge, BECKMAN COULTER). The supernatant was 
discarded and the pellet was resuspended in 600 µl of sterile H2O. The entire contents were 
transferred into a 1.5 ml Eppendorf tube and 100 µl of 7X Lysis buffer was added and gently 
mixed by inversion. Afterwards 350 µl of cold neutralization buffer was added and 
thoroughly mixed. The supernatant was aliquoted into the preassembled Zymo-Spin
TM
 IIN 
filter column and centrifuged at 11 000 rpm for 4 min (Centrifuge 5418, Eppendorf). The 
flow through was discarded and the column was washed twice using 200 µl Endo-Wash 
buffer and 400 µl Wash buffer with one min centrifugations at 11 000 rpm respectively. The 
flow-through was discarded and the column was transferred to a clean 1.5 ml microcentrifuge 
tube. Finally, 50 µl of the ZyppyTM Elution buffer was added directly onto the column matrix 
oligo 
pLJR962_ribF8 ribF knockdown construct 
created by insertion of sgRNA8 
oligo 
This study 
pLJR962_ribF9 ribF knockdown construct 
created by insertion of sgRNA9 
oligo 
This study 
pLJR962_ribF10 ribF knockdown construct 
created by insertion of sgRNA10 
oligo 
This study 
pLJR962_mmpL3 mmpL3 knockdown construct 






and was incubated at room temperature for one min. Ultimately, the plasmid DNA was eluted 
by centrifugation at 10 000 rpm for two min. Approximately 500 ng of each sample was sent 
for sequencing for confirmation of sgRNA inserts at the Central Analytical Facilities (CAF), 
University of Stellenbosch. Verified constructs were electroporated into Msm. 
2.1.4 DNA manipulations 
Standardized protocols were adopted from (Sambrook et al., 1989; Sambrook &Russell 
2001) for all DNA manipulations and biological molecular techniques. 
2.1.4.1 Agarose gel electrophoresis 
The pLJR962 CRISPRi backbone was digested with BsmBI and run on a 1% agarose gel for 
purification. The gel was prepared by dissolving 0.8 g agarose (Sigma-Aldrich) powder with 
100 ml of 1 x TAE (40 mM Tris-acetic acid, 1 mM Na2EDTA pH 8.0) buffer with 1 µl of 10 
mg/ml ethidium bromide (EtBr). Approximately 1000 ng of the vector DNA was combined 
with loading dye (0.025% bromophenol-blue in 30% glycerol) for tracking. A DNA 
molecular weight marker (Roche Applied Science, Germany) was used to approximate the 
DNA fragment size of the template DNA. Electrophoresis was carried out using the Mini-
Sub® cell GT with a submerged horizontal unit (Bio-Rad) set at 90 V and run for 40 min. The 
gel was viewed using the Gel dock (WealTech Ketagalan Imaging System) under ultraviolet 
(UV) light.  
2.1.4.2 Gel extraction and quantification 
The desired DNA fragment was cut out using a scalpel and purified following the 
manufacturer’s instructions using the NucleoSpin® Extraction II kit, Macherey Nagel. The 
excised DNA fragment from the agarose gel was resuspended and incubated in DNA-binding 
buffer for 20 min at 50ºC. The dissolved gel solution was loaded on the NucleoSpin® Gel and 
PCR Clean-Up Midi column which was washed twice with wash buffer. Finally, the purified 
and digested pLJR962 vector backbone was eluted in 50 µl of elution buffer and quantitated 
using the NanoDrop ND-1000 spectrophotometer (Thermo Scientific). 
2.1.4.3 Restriction digests 
The vector backbone was digested with the restriction enzyme BsmBI (NEB) and incubated 
at 55ºC. Approximately 1 µg of the plasmid DNA was digested for 1 hour incubated on a 
compact thermomixer (Eppendorf) with 10 µl of 1 x CutSmart® buffer containing 1 µl of the 




ligation was limited and dephosphorylation was unnecessary. Desired fragments were 
analysed and validated by running the digest on a 0.8% agarose gel.  
2.1.4.4 SgRNA oligo annealing 
4 µl of the forward and reverse oligo were added to 42 µl of annealing buffer (50 mM Tris, 
50 mM NaCl and 1 mM of EDTA, pH 7.5) to obtain a total volume of 50 µl. The annealing 
conditions were set at a denaturation phase of 95ºC for 2 min followed by an annealing step 
incorporating a decline in temperature from 95ºC to 25ºC at a 0.1ºC per second interval 
(T100
TM
 Thermal cycler, BioRad).  
2.1.4.5 Ligation 
0.5 µl (2.7x10-7 nmol) of the annealed complementary sgRNA targeting oligos were added to 
9 ng (1.56x10
-9
 nmol) of the BsmBI digested vector. The ligation mixture was set up as 
follows; 0.5 µl of annealed oligos, 1 µl of digested vector, 2.5 µl of 1 x Quick buffer and 0.5 
µl of Quick ligase (NEB) were added to a microtube and incubated at room temperature for 
30 min followed by ligase inactivation on ice.    
2.1.5 Bacterial transformation 
2.1.5.1 Escherichia coli 
2.1.5.1.1 Preparation of competent cells 
E. coli DH5α cells were made transformation competent using rubidium chloride. Briefly, 
100 µl of an E. coli freezer stock was inoculated in 5 ml of LB broth and incubated at 37ºC in 
a shaking incubator overnight. One ml of the overnight culture was inoculated into 99 ml of 
LB broth and allowed to grow at 37ºC to reach an OD600 of 0.8. The cultures were then 
incubated on ice for 15 min prior to being centrifuged at 4000 rpm for 5 min at 4ºC 
(Allegra
TM 
X-22R Centrifuge, BECKMAN COULTER). The pellet was resuspended in 40 ml 
of Transformation buffer I (30 mM potassium acetate, 100 mM rubidium chloride, 50 mM 
manganese chloride and 15% (v/v) glycerol, pH 5.8) (Tfb I) and incubated on ice for 15 min. 
The cells were spun down at 3000 rpm for 5 min and resuspended in 4 ml of Tfb II (10 mM 
MOPS, 75 mM calcium chloride,10 mM rubidium chloride and 15% (v/v) glycerol, pH 6.5. 
Competent cells were quick frozen in 500 µl aliquots and stored at -80ºC until required. 
 
2.1.5.1.2 Transformation of plasmid DNA into competent E. coli cells 
Competent DH5α cells were allowed to thaw and 500 ng of recombinant plasmid (sgRNA + 




briefly heated to 42ºC for 90 seconds and were immediately placed back on ice for 2 min. 
The cells were rescued by the addition of 200 µl of 2 x TY (Tryptone Yeast) broth and 
incubated at 37ºC for 1 hour in a standing incubator (IncoCool incubator, LaboTech). The 
entire contents were plated onto LA agar containing 50 µg/ml Kan for selection. The plates 
were then incubated at 37ºC overnight in a stationary incubator (IncoCool incubator, 
LaboTech). 
2.1.5.2 Mycobacterium smegmatis 
2.1.5.2.1 Preparation of Msm electro-competent cells 
A MSM_WT mc2155 culture was inoculated in 7H9-OADC and incubated overnight at 37ºC 
to reach an OD600 of ~ 0.6 (Incoshake incubator, LaboTech). The cells were spun down in a 
centrifuge (Allegra
TM 
X-22R Centrifuge, BECKMAN COULTER) at 4000 rpm at 4ºC for 10 
min and washed three times using cold 10% (v/v) glycerol. Washes were carried out 
sequentially resuspended in 25 ml, 10 ml and 5 ml, respectively. Finally, the pelleted cells 
were resuspended in 1.8 ml of 10% (v/v) glycerol and distributed in 300 µl aliquots and 
stored at -80ºC until required. 
2.1.5.2.2 Electroporation of recombinant plasmid into Msm cells 
The competent Msm cells were gently thawed and aliquoted into pre-chilled electroporation 
cuvettes (0.2 cm electrode gap, Bio-Rad) containing ~ 500 ng of recombinant plasmid DNA. 
The GenePulser
TM
 (Bio-Rad) was set at 2.5 kV, 1000 Ω resistance and 25 µF capacitance. 
Cells were rescued after pulsing by adding 600 µl of 2 x TY to the cuvette and incubated at 
37ºC overnight in a stationary incubator (IncoCool incubator, LaboTech). The following day, 
the contents were transferred into a clean 1.5 ml microcentrifuge tube and pelleted down at 
10 000 rpm for 2 min (Centrifuge 5418, Eppendorf). The cells were then resuspended in 100 
µl of 7H9-OADC and the entire contents plated on 7H10-OADC agar containing 25 µg/ml 
Kan and incubated at 37ºC for 3-5 days in a stationary incubator. 
2.1.6 DNA sequencing 
The presence of all sgRNA inserts in respective constructs was validated by sequencing, 
conducted by the Central Analytical Facility (CAF) at the University of Stellenbosch. 
Sequencing reads were conceptualized using FinchTv 1.4.0 free software 
(https://digitalworldbiology.com/finchTv) and compared to the predicted sgRNA sequence to 




Table 2.3: Primer used in this study for sequencing sgRNA insert 










2.1.7.1 Sample preparation for detecting transcript levels  
Strains were inoculated at an initial inoculum concentration of an OD600 of 0.016 in 7H9-
OADC media containing either no ATc or 100 ng/ml ATc, including 25 µg/ml Kan where 
relevant. The cultures were allowed to grow for 24 hours in a shaking incubator at 37ºC 
(Incoshake incubator, LaboTech). The entire contents were transferred into Falcon tubes 
post-incubation and centrifuged at 4500 rpm for 10 min (Allegra
TM 
X-22R Centrifuge, 
BECKMAN COULTER). The supernatant was discarded and the pellet resuspended in 1 ml 
of 7H9-OADC and transferred into clean 2 ml Eppendorf tubes. The cultures were washed 
twice by spinning down at 10 000 rpm for 10 min in a microcentrifuge (Centrifuge 5418, 
Eppendorf). Finally, the supernatant was discarded and remaining cells were resuspended in 
500 µl of LBP Lysis buffer (Nucleospin® RNA plus kit) and stored at -80ºC in preparation 
for RNA extraction.    
2.1.7.2 RNA isolation 
The resuspended LBP lysis buffer samples were processed according to the manufacturer’s 
protocol using the Nucleospin® RNA plus kit (Macherey-Nagel). Briefly, the samples were 
allowed to gently thaw on ice and transferred into 2 ml Homogenization microtubes 
containing silica lysing matrix (ZIRCONIA/SILICA 0.1 mm in diameter, BioSpec). Samples 
were sealed with parafilm and lysed using the cell disrupter (FastPrep
TM 
FP120, BIO 101 
Savant) set at speed 5 for 30 seconds. This was repeated three times separated by 2 min 
incubations on ice. The samples were spun down at 10 000 rpm for 10 min using a 
microcentrifuge and the supernatant was transferred into a genomic DNA removal tube 
before transferral into an RNA selective binding column (NucleoSpin® RNA Plus kit, 




DNA contaminants were digested with TURBO DNAse treatment (Invitrogen). Briefly, the 
eluent was treated by adding 0.1 the volume of TURBO DNAse buffer and 2 units of enzyme 
and incubated at 37
º
C for 1 hour. Following the incubation, 0.1 the volume of Inactivation 
reagent was added to the mixture, briefly centrifuged and the supernatant transferred to a new 
tube. The resultant DNA-free RNA was used to synthesize cDNA by addition of 1 µl of 50 
µM random hexamers, 1 µl of 10 mM dNTP and 12 µl of 250 ng template RNA including 0.5 
µl of SuperScript® IV Reverse Transcriptase, added to appropriate samples in preparation for 
qRT-PCR (SimpliAmp Thermal Cycler, Thermo Fisher Scientific). A no reverse transcriptase 
control was included to verify the absence of DNA contamination.  
2.1.7.3  Junction amplification method used to identify single transcriptional 
units via junction primers 
To establish if the RF genes constitute a single transcriptional unit, RNA was extracted and 
converted to cDNA as previously described in section 2.1.7.2 from MSM_WT and primers 
were designed to amplify the junctions between two genes. Five primers were designed to 
amplify the region between genes: MSMEG_3070-ribE (147 bp), ribE-ribAB (166 bp), 
ribAB-ribH (110 bp), ribH-MSMEG_3074 (306 bp) and MSMEG_3074-MSMEG_3075 (250 
bp). The constitutive and highly expressed sigA gene was amplified as a positive control.  
 
Table 2.4: List of junction primers used to validate genes constituting a single transcriptional 
unit   






 qRTMSM3070-ribE REV -GAACAAGGACTGGACTGCGAA- 
ribE-ribAB qRTMSM ribE-ribAB 
FWD 
-GGGTACGGGTCGGTAAGAG- 
 qRMSM ribE-ribAB 
REV 
-CGCCCTCTCGACGGAATC- 

























2.1.7.4 Quantitative measurement of transcript levels of target genes by qRT-
PCR    
The Power SYBR® Green PCR Master mix was used in a 96-Well Piko PCR Fast Plateᵻ with 
the forward and reverse primer constituting a final concentration of 0.3 µM in conjunction 
with cDNA template DNA, which resulted in a 20 µl volume per reaction. The thermal 
cycling parameters were set as follows: AmpliTaq Gold® Enzyme Activation was on hold for 
10 min at 95ºC followed by denaturation at 95ºC for 15 seconds. The annealing and extension 
steps occurred at 60ºC for 60 seconds for 40 PCR cycles (PikoReal 96 Real-Time PCR 
System, Thermo Scientific). The absolute transcript expression levels of target genes were 
calculated in copies/µl and normalized to sigA. Comparable ratios between the normalized 
transcript levels of ATc induced versus non ATc induced strains were used to infer 








Table 2.5: List of primers used for qRT-PCR reactions to study transcriptional expression 
levels. 
Gene Primer ID Primer sequences (5’-3’) 
sigA qRT_MSM_sigAFWD -ACCAAGGGCTACAAGTTCTCG- 
 qRT_MSM_sigAREV -CATCTCCTTGGCGAGCTCTTC- 
dCas9 qRT_MSM_dCas9FWD -TCGGTGAAGCTGATGATGGAG- 
 qRT_MSM_dCas9REV -TGTAGATCTCCTCGGTCAGCA- 
ribF qRT_MSM_ribFFWD -GATCGACGTGTTCCTGGTGAT- 
 qRT_MSM_ribFREV -CAGCATGTCGACGTTGCC- 
mmpL3 qRT_MSM_mmpL3FWD -AACGATCCGGAGAAGATGTGG- 
 qRT_MSM_mmpL3REV -CGCAACTCGTCGATCTTCTTG- 
 
Table 2.6: List of primers used for qRT-PCR of the proposed rib operon, quantified by 
transcript expression levels 
Gene Primer ID Primer sequences (5’-3’) 
ribE (MSMEG_3071) qRT_MSM_ribEFWD -TTGGTGATGACTGGTTTGAGA- 
 qRT_MSM_ribEREV -ATGACGTCCACTTCCAGGTTC- 
ribAB (MSMEG_3072) qRT_MSM_ribABFWD -GCCGACGATTTCACCAAGC- 
 qRT_MSM_ribABREV -GTCCTTCTGGCTGACGATCTC- 
ribH (MSMEG_3073) qRT_MSM_ribHFWD -GACCACCAACACCGAGGAG- 
 qRT_MSM_ribHREV -ACGGCGGTGGACAGTG- 
 
2.1.8 Transcriptional downregulation of target genes by CRISPRi 
A wide range of sgRNAs targeting Msm genes were designed and described by (de Wet et al. 




bottom oligo usually 20 to 25 bases in length which targeted ribF, involved in the RF 
pathway. The oligos were ligated into the BsmBI-digested vector backbone. Ligated 
recombinant plasmids were transformed into DH5α E. coli cells and plated on 50 µg/ml Kan 
LA agar containing plates. Plasmid DNA extraction was performed from single colonies and 
were sequenced using sequencing primer 1834 (Table 2.3) via Sanger sequencing to validate 
the presence of the insert. A control construct was also generated targeting mmpL3, an 
essential gene involved in the biosynthesis of the mycobacterial cell wall, also shown to be 
highly susceptible to transcriptional depletion. As a negative control, the CRISPRi vector 
without a sgRNA was used to illustrate that the plasmid itself does not have an effect on the 
growth or viability of the cells. Validated sgRNA carrying constructs were electroporated 
into competent Msm cells. Single colonies were grown in 7H9-OADC supplemented media 
containing 25 µg/ml Kan. An ATc MIC was performed to induce gene knockdown where 
growth was measured using alamar blue as described in the MABA assay (Collins & 
Franzblau, 1997). A detailed explanation of this procedure is provided below in section 
2.1.9.1 Determination of ATc MIC in liquid media.  
2.1.9 Phenotypic Characterization 
2.1.9.1 Determination of ATc MIC in liquid media  
Cultures were grown in 7H9-OADC containing 25 µg/ml Kan where relevant to reach an 
OD600 of 0.5 and incubated at 37ºC in a shaking incubator (Incoshake incubator, LaboTech). 
Using a U-bottom 96 well microtiter plate (Greiner bio-one, CELLSTAR®), the assay was set 
up as follows; 50 µl of 7H9-OADC was added to columns 2 to 12. 100 µl of 7H9-OADC 
containing 400 ng/ml ATc stock was added to column 1. A two-fold dilution was carried out, 
50 µl of the contents in column 1 were mixed 5-8 times by suctioning up and down with a 
multi-channel pipette before being transferred into column 2 and so forth until the end of the 
plate was reached and the remaining 50 µl was discarded. Each plate included a media only 
control row to confirm the absence of contamination. Finally, 50 µl of each 1: 1000 diluted 
culture was added to its respective row and plates were covered in foil and incubated at 37ºC 
in a stationary incubator for 24 hours (IncoCool incubator, LaboTech). Ten µl of a 0.01% 
Alamar blue solution (Resazurin) was added to each well using a 12-way multichannel 
pipette and plates were re-incubated for an additional 8 hours. Lastly, fluorescent readings 




and excitation wavelength of 590 nm and 544 nm, respectively, and images were captured 
using an inverted mirror.  
In addition, a similar assay was carried out to demonstrate if the hypomorphs could access 
and survive by scavenging exogenous riboflavin metabolites. The metabolites tested were 
riboflavin (RF), flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) 
(Sigma-Aldrich). The U-bottom 96 well microtiter plate was prepared as follows; 50µl of 200 
ng/ml ATc diluted in 7H9-OADC media was added to columns 2 to 12. One hundred µl of a 
1 mg/ml RF or FMN or FAD stock was added to each respective row in column 1. As 
described previously, a two-fold dilution was conducted and the plates processed in the same 
way as mentioned above. Similarly, the MIC90 analysis was used to determine the minimum 
inhibitory concentration of proposed FAD synthetase inhibitors against MSM_WT and 
starting concentrations of drugs used in this assay were as follows; 200 µM alexidine 
dihydrochloride, 200 µM benzethonium chloride, 200 µM roseoflavin, 200 µM ribocil-C, 200 
µM PAS, 200 µM verteporfin, 200 µM thonzonium bromide and 552 µM vancomycin. 
2.1.9.2 Spotting assay to assess growth inhibition on solid media 
Cultures were allowed to grow at 37ºC overnight to reach an OD600 of 0.5 (Incoshake 
incubator, LaboTech). A 1:1000 dilution was performed and 100 µl of each sample was 
added to the first column of each respective row. The diluted cultures were then serially 
diluted in a 2-fold dilution series. Approximately 5 µl of each dilution was spotted on 7H10-
OADC containing 100 ng/ml ATc or no ATc (0 ng/ml). The spotted cultures were allowed to 
fully absorb prior to incubation. Finally, plates were covered in foil and incubated at 37ºC for 
2-3 days (IncoCool incubator, LaboTech) and images were captured. 
2.1.9.3 2D Checkerboard Assay 
This assay was used to demonstrate any potential synergy between the gene knockdown 
mutants and potential FAD synthetase inhibitors. The 96-well U-bottom plate was prepared 







An additional 50 µl of media was added to column 2 and 12 as well as B2 to B11. 
Lastly, 50 µl of media was added to well B2 to obtain a final volume of 200 µl.  
 
4 µl of drugx was added to B2 and 2 µl of the same drug added to B3 to B11 and 
serially diluted in 2-fold dilutions by thoroughly mixing 5-8 times before transferring 100 µl 
contents from B2 into C2 until H2. Similarly, 50 µl of contents of B3-B11 were serially 
diluted in 2-fold dilutions until H3-H11 using a 12-way multichannel pipette and the residual 
50 µl was discarded. 2 µl of 2500 ng/ml ATc was added to the entire column 3 and 50 µl of 





Finally, 50µl of a 1: 1000 dilution of an OD600 0.5 culture was added to all 8 rows 
besides the media only control, column 12. The plates were then covered in foil and placed in 
a zippy bag (SIGMA) to prevent liquid evaporation. Lastly, the plates were incubated at 37ºC 
for 24 hours in a stationary incubator (IncoCool incubator, LaboTech). Post incubation, 10 µl 
of 0.01% Alamar blue was added to each well and plates were re-incubated at 37ºC for an 
additional 8 hours. The metabolic activities of live versus dead cells were measured using the 
plate reader (FLUOstar Optima, BMG LabTech) and images were captured using an inverted 
mirror. 
Starting concentrations of drugs used in this assay per plate were as follows; 2500 
ng/ml anhydrotetracycline (ATc), 80 µM alexidine dihydrochloride, 2500 µM benzethonium 
chloride, 10000 µM thonzonium bromide and 552 µM vancomycin. 
2.1.9.4 Assessment of mycobacterial growth and viability 
Cultures were incubated at 37ºC and allowed to grow overnight to reach exponential phase 
OD600 of 0.5 (Incoshake incubator, LaboTech). 25 ml of 7H9-OADC media was added to 
Erlenmeyer flasks containing 25 µg/ml Kan and no ATc or supplemented with 100 ng/ml 
ATc. A 0.004 starting inoculum per strain was added to relevant flasks and incubated at 37ºC 
in a shaking incubator for 24 hours. The OD600 readings were measured in 3 hour intervals 
over a 24 hour period using a spectrophotometer (Novaspec Plus visible spectrophotometer, 
Amersham Biosciences). Simultaneously, 1 ml of each sample was harvested, washed twice 
and resuspended in the same volume of media prior to plating (Centrifuge 5418, Eppendorf). 
Samples were serially diluted in 10-fold dilutions and 100 µl of each dilution factor was 




allowed to fully absorb overnight and placed in bags and incubated at 37ºC for 3-5 days 
(IncoCool incubator, LaboTech). Colonies were manually counted post 5-days of incubation 
and CFUs recorded.      
2.1.9.5 Assessment of gene knockdown mutants exposed to varying 
concentrations of ATc 
Cultures were incubated at 37ºC and allowed to grow overnight to reach exponential phase 
OD600 of approximately 0.5 (Incoshake incubator, LaboTech). 25 ml of 7H9-OADC media 
was added to Erlenmeyer flasks containing 25 µg/ml Kan and supplemented with decreasing 
concentrations of ATc set at 100 ng/ml, 50 ng/ml, 25 ng/ml, 12.5 ng/ml, 6.3 ng/ml, 3.125 
ng/ml, 1.6 ng/ml, 0.8 ng/ml, 0.4 ng/ml, 0.2 ng/ml and 0.1 ng/ml, and no ATc. A 0.004 
starting inoculum was inoculated into relevant flasks and incubated at 37ºC in a shaking 
incubator for 24 hours. The OD600 readings were measured in 3 hour intervals over a 24 hour 
period using a Novaspec Plus visible spectrophotometer (Amersham Biosciences). 
2.1.9.6 Assessment of inoculum effect on the CRISPRi system 
Cultures were incubated at 37ºC and allowed to grow overnight to reach stationary phase at 
an OD600 of approximately 1.0 (Incoshake incubator, LaboTech). 25 ml of 7H9-OADC media 
was added to Erlenmeyer flasks containing 25 µg/ml Kan either in the presence of 100 ng/ml 
ATc or absence of ATc. Increasing starting inoculum concentrations of an OD600 of 0.004, 
0.016, 0.06 and 0.25 per strain were added to relevant flasks and incubated at 37ºC in a 
shaking incubator for 12 hours to induce transcriptional knockdown. The OD600 readings 
were measured in 3 hour intervals over a 12-24 hour period using a Novaspec Plus visible 
spectrophotometer (Amersham Biosciences). 
2.1.9.7 LC-MS sample preparation  
Cultures were grown to log-phase overnight at 37ºC in a shaking incubator (Incoshake 
incubator, LaboTech). A starting inoculum of 0.016 was inoculated in 10 ml of 7H9-OADC 
supplemented media containing 25 µg/ml Kan. Each strain was exposed to either 100 ng/ml 
or 0 ng/ml ATc and incubated at 37ºC to induce CRISPRi-mediated gene silencing. Each 
sample was washed twice and resuspended in 1000 µl of 50 mM sodium acetate (NaOAc pH 
4.5) following a 10 min centrifugation at 10 000 rpm. This was stored at -80ºC until 




2.1.9.7.1 Metabolite extraction 
The samples were allowed to gently thaw on ice. Each sample was sonicated at the following 
settings; amplitude of 30, process time of 5 min and pulse-on and off time of 15 seconds  
(Q700 Qsonica, Sonicators). The samples were spun down at 13 000 rpm for 5 min and the 
supernatants transferred into  falcon tubes topped with 4 ml of sodium acetate buffer. The 
mixture was loaded onto a pre-equilibrated C18 cartridge and washed using 10 ml of sterile 
water. Seventy-five percent of ethanol (EtOH) was used to elute ~ 15 drops of each sample 
into a clean 1.5 ml Eppendorf tube and dried for approximately 2 hours at 50ºC in a miVac 
DNA concentrator, GeneVac. All dried samples were appropriately stored at -20ºC in 
preparation for LC-MS analysis. 
2.1.9.7.2 LC-MS analysis of RF metabolites in Msm 
 The pellet was reconstituted in (A:B at 1:1 ratio) whereby A represents H2O (0.02 % Formic 
Acid; 2mM Ammonium Formate) and B refers to Methanol (0.02 % Formic Acid; 2mM 
Ammonium Formate). Three ul of each reconstituted sample was injected into the high 
performance liquid chromatography mass spectrophotometer (SHIMADZU 8040)  on a 
reverse-phased (C18) column run at a flow rate of 0.8 ml/min with ESI detector run with A:B 
(1:1) mobile phase (Phenomenex Kinetex 2.6u phenyl-hexyl (4.6 X 100mm))  Multiple 
reaction monitoring (MRM) was assembled for each of the reference standards, i.e. FMN, 
FAD, RF, DMRL and vitamin B12, at three sequential levels (high, medium and low). The 
difference of all tested RF metabolite peaks were compared in relation to Msm WT and no 
ATc ribF treated cells to validate metabolic differences in the pathway. 
2.1.9.7.2.1 Bradford Protein assay to measure total protein 
content 
2.1.9.7.2.1.1 Normalization of protein content between -
/+ ATc CRISPRi KDs 
Five dilutions of the protein standard, Bovine Serum Albumin (BSA) were prepared ranging 
from 1.8-0.05 mg/ml. One hundred µl of each standard was aliquoted separately into a clean 
falcon tube and resuspended in 5 ml of 1:4 diluted dye reagent (Bio-Rad Protein Assay Dye 
Reagent Concentrate). The samples were thoroughly mixed and incubated at room 
temperature for 5 min prior to absorbance measurement. Finally, 1 ml of each sample was 
aliquoted in a UV-cuvette and absorbance was measured at 595 nm using the 




likewise processed to obtain absorbance values; the standard curve was then used to 
enumerate the corresponding protein concentration (Figure 2.1). 
 
Figure 2.1: Bradford assay used to enumerate the protein concentration based on the equation 
generated from the standard curve. Protein concentrations of the uninduced and induced hypomorph 
strains were adjusted to approximately 1 mg/ml.  
 
2.1.10 Whole Genome Sequencing 
2.1.10.1 Sample preparation for genomic DNA extraction (gDNA) 
Cultures were grown as mentioned in the assessment of mycobacterial growth and viability 
section 2.1.1 Bacterial strains, plasmids and growth conditions. After a 5 day incubation, 
one colony from each plate was carefully picked and inoculated into 1 ml of 7H9 and allowed 
to grow at 37ºC to reach stationary phase (Incoshake incubator, LaboTech). These pre-
cultures were used to inoculate into 50 ml of 7H9 containing 25 µg/ml Kan where appropriate 
and grown overnight. The cultures were centrifuged at 4000 rpm for 15 mins (Allegra
TM 
X-
22R Centrifuge, BECKMAN COULTER) and resuspended in 500 µl of TE buffer (10 mM 
Tris, 1 mM EDTA, 25 mM NaCl, pH 8.0). Each of the resuspended cultures were transferred 
into 2 ml Eppendorf tubes and stored at -80ºC until isolation of gDNA from Msm was 
underway. 
y = 2,0226x - 0,9093 

































2.1.10.2 Cetyl Trimethyl Ammonium Bromide (CTAB) extraction of 
gDNA from Msm 
This protocol was adapted from van Helden et al., 2001 where cells were allowed to gently 
thaw at room temperature and 50 µl of lysozyme (10 mg/ml)  was added for digestion 
overnight at 37ºC on a thermomixer (Thermomixer compact, Eppendorf), rotating at a 
moderate speed of 300 rpm. Following lysozyme treatment, ~ 1.3 µl of RNAse (10 mg/ml) 
was added to each tube and incubated at 37ºC for an additional hour. Next, 70 µl of 10% SDS 
and 50 µl of proteinase K were simultaneously added and incubated at 65ºC for an hour. In 
addition,  100 µl of 5M NaCl and 10% of CTAB were added and incubated at 37ºC for 15 
mins at low-mode shaking speed. Following the 15 mins incubation on the thermomixer, 700 
µl of a (24:1) chloroform: isoamyl alcohol solution was added to each tube and pelleted down 
at 13 000 rpm for 10 mins, to harvest the DNA (Centrifuge 5418, Eppendorf). After 
centrifugation, approximately 700 µl of the aqueous phase was transferred into a new 2 ml 
Eppendorf tube and mixed with an equivalent volume of cold isopropanol to precipitate the 
DNA. The tubes were left at -20ºC overnight. The following day samples were centrifuged at 
13 000 rpm for 10 mins and the supernatant was carefully discarded and the pellet washed in 
800 µl of 70% EtOH. Lastly, the samples were drained of EtOH and dried at 40ºC in a Speed 
Vac (miVac DNA concentrator, GeneVac). All samples were quantitated using the Nanodrop 
to determine their concentration (NanoDrop ND-1000 spectrophotometer, Thermo Scientific) 
and run on an agarose gel  using the same parameters as 2.1.4.1 Agarose gel electrophoresis 
with a high molecular weight ladder , Marker III (Roche Applied Science, Germany). 
 
2.1.11 Bioinformatics analysis tools 
i) Gene identifier: The Mycobrowser (http://mycobrowser.epfl.ch) database was 
used to identify the gene of interest, ribF, and homologs found in other 
mycobacterial species such as M. leprae and Mtb (Supplementary table 1). This 
database was also used to identify surrounding genes in close proximity to ribF to 
establish its genomic context (Supplementary figure S1) (Kapopoulou, Lew & 
Cole, 2011). 
The GenoList – Institut Pasteur (http://genolist.pasteur.fr) genome browser 





ii) Pathway predictor: The KEGG: Kyoto Encyclopedia of Genes and Genomes – 
GenomeNet (www.genome.jp/kegg/) database was used to validate and map out 
all genes involved in the RF biosynthetic pathway. 
iii) Riboflavin chemical conversion identifier: The BioCyc Pathway/Genome 
Database Collection (https://biocyc.org/) was used to identify and reconstruct 
chemical conversions of RF to FMN and from FMN (Riboflavin-5’-phosphate) to 
FAD. 
iv) Secondary structure identifier: The psiprep: index – UCL 
(http://bioinf.cs.ucl.ac.uk/psiprep/) database was used to visualize secondary 
structures of RibF in M. smegmatis and B. subtilis (RibC and RibR). 
v) Chemical structure constructer: The PubChem Sketcher V2.4 
(https://pubchem.ncbi.nlm.nih.gov/edit2/index.html) database was used to 
construct  any drug chemical compound structures 
vi) Clustal alignment identifier and phylogenetic tree constructer: The Clustal 
Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/ database was used to construct 
a phylogenetic tree to observe the relevance and evolutionary relatedness amongst 
M. smegmatis, Mtb, M. leprae, E. coli, and B. subtilis ribF homologs. 
vii) Protein domain predictor: The InterPro protein sequence analysis & 
classification database (https://www.ebi.uk/interpro/) and the protein BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) database were used for 
the prediction of protein domains of RibF in model bacteria and Mycobacteria. 
viii) Statistical analysis: Graphical representation of results and statistical variations 
in phenotypic features were analysed using the GraphPad Prism 7.04 software.  
ix) Protein structure predictor: Protein Homology/analogY Recognition Engine 
version 2.0 was used to predict and analyse protein structures. The amino acid 
sequences of all tested mycobacterial proteins were accessed from Mycobrowser 
(https://mycobrowser.epfl.ch) with the human proteins obtained from NCBI. 
These sequences were pasted onto the amino acid sequence and the job was 
logged in after clicking the Phyre search tab. The server was accessed at 
































3.1 Selection and design of sgRNAs  
Single guide RNAs (sgRNAs) are short oligonucleotides (oligos) that are complementary to 
the nucleotide sequence in the target gene of interest and are essential in mediating dCas9-
sgRNA complex binding to the DNA to block RNA transcription by either occluding RNA 
polymerase access to the target promoter or steric blockage of transcription elongation (Rock 
et al. 2017). The sgRNAs were designed using a published algorithm (de Wet et al. 2018) 
which scans the length of the gene sequence, recognizing repetitive 2-6 bp protospacer 
adjacent motif (PAM) sequences that correlate with appropriate sgRNA binding sites. Ten 
potential targeting sites were identified within the ribF gene. The algorithm computationally 
assigned a score to each sgRNA sequence to predict the efficacy of transcriptional 
knockdown (Rock et al. 2017). Based on this scoring system, sgRNAs with low PAM scores 
were likely to cause the most efficient gene knockdown (Table 3.1; Figure 3.1).  
Table 3.1: List of sgRNA oligos used to generate the constructs to knockdown the 

























Figure 3.1: Distribution of sgRNAs designed to target Msm ribF. (A) The black line represents the length of the gene and each highlighted sequence represents an 
individual sgRNA  in the DNA sequence of ribF annotated from 5` to 3`. The asterisk (*) indicates an sgRNA that was predicted to be the most effective targeting guide 
based on PAM score. Individual PAM scores are annotated above each sgRNA coloured box.  (B) The bifunctional RibF comprises two domains, namely FAD synthetase_N 




An optimized mycobacterial CRISPRi system (Rock et al. 2017) was used to 
investigate gene essentiality through transcriptional interference of ribF by monitoring the 
effect of its depletion on mycobacterial viability. To investigate the efficacy of the sgRNAs 
experimentally, each sgRNA (Figure 3.1) was used to create a gene knockdown construct, a 
20 to 25 bp oligo constructed by a short PCR annealing of a Fwd and Rev primer. The 
sgRNA construct was cloned into a BsmB1 digested CRISPRi (pLJR962) plasmid and 
transformed into DH5α E. coli cells. Sequence verification of positively incorporated 
sgRNAs was carried out by Sanger sequencing prior to electroporation into wild type Msm 
mc
2
155 to generate inducible gene knockdown mutants or “hypomorphs” (Figure 3.2). 
Following electroporation, this plasmid integrates into the L5 site where it expresses both the 
sgRNA and the deactivated Cas9 (dCas9) under the control of the inducible 
anhydrotetracycline promoters. Phenotypic validation of the efficacy of knockdown and the 
level of gene repression associated with each guide was assessed using the microplate alamar 






Figure 3.2: Tailoring CRISPRi knockdown mutants. Step 1 Oligos were designed to target Msm 
ribF. Step 2 The oligos were commercially synthesized. Step 3 sgRNAs were constructed through 
PCR annealing of the Fwd and Rev oligos. Step 4 Each sgRNA was cloned into the pLJR962 
plasmid. Step 5 The recombinant plasmid was transformed into E. coli. Step 6 Potential transformants 
carrying sgRNA constructs were validated by Sanger sequencing. Step 7 Constructs were finally 
electroporated into Msm. Step 8 Lastly an ATc MIC assay was carried out to measure the efficacy of 
each sgRNA. 
3.2 Utilization of CRISPRi to probe the essentiality of Msm ribF 
The sgRNAs were used to generate 10 hypomorphs (gene knockdown mutants) (Figure 3.2). 
In addition, 3 control strains were used throughout this project: (i) a hypomorph targeting 
mmpL3 (MSM_MmpL3), a known essential gene required for trehalose mono-mycolate 
transportation across the inner membrane (Xu et al. 2017a), which was used as to 
demonstrate efficient gene repression using the CRISPRi system (McNeil and Cook 
2019a),(ii) a vector-only Msm control strain (MSM_Vector) with no targeting sgRNA to 
ensure that the vector backbone had no adverse effects on cell growth and (iii) the wild type 
mc
2
155 parental strain (MSM_WT) which was expected to phenocopy the vector-only 
control.  
3.2.1 Phenotypic validation of transcriptional downregulation as a result of CRISPRi 
induction in Msm 
It was critical to investigate the strength of transcriptional repression of each sgRNA to 
identify the most efficient guides and to establish if these correlated to that which had been 
predicted computationally. To test this, mycobacterial cultures were grown to an exponential 
phase of an OD600 of 0.5 (hereafter referred to as exponential phase) and were serially diluted 
in 2-fold increments before spotting onto media either without ATc (uninduced) or containing 
100 ng/ml ATc to induce CRISPRi-mediated repression. These results demonstrated that, as 
predicted, the strength of transcriptional knockdown was inversely proportional to the 
calculated PAM score: 7 of the guides (RibF1-7) with PAM scores ranging from 5-11 elicited 
the most effective growth repression. The remaining 3 guides, RibF8-10, did not result in 
discernible growth inhibition. Notably, no clear trend relating guide efficacy to position 
within the gene was detected; that is, as reported previously (Rock et al. 2017; de Wet et al. 
2018), location closer to either the 5` or 3` terminus did not yield any bias towards better 




controls were unaffected, in contrast, the growth of MSM_MmpL3 was potently inhibited 
(Figure 3.3).   
 
 
Figure 3.3: CRISPRi-mediated growth inhibition via ribF repression. Spotting assays of exponential phase 
cultures in 2-fold dilutions on standard 7H10 medium without ATc (-ATc) (Left) and with ATc (+ATc) (Right). 
Strain names are indicated on the left of the images. Results represent one of the three biological replicates. The 




This assay was also performed in liquid medium in a broth microdilution assay in 
which all strains were again grown to exponential phase and exposed to a range of ATc 
concentrations. In this assay, the first 5 strains, RibF1-5, were highly repressed in the 
presence of ATc (as evident from the reduction in fluorescence) and were responsive to ATc 
concentrations as low as 1.6 ng/ml. RibF6 and RibF7 were not as responsive to ATc in the 
liquid assay. Based on the solid and liquid phenotypes observed with the 10 hypomorphs, 
MSM_RibF1 (hereafter referred to as MSM_RibF) was selected for use in all further 
experiments (Figure 3.4). 
 
Figure 3.4: Growth responsiveness of RibF hypomorphs to different concentrations of ATc. Each bar 
represents the relative fluorescence percentage (%) determined at the corresponding ATc concentration. Relative 
fluorescent percentages were calculated such that the raw experimental values were divided by the average row 
of the uninduced cells only control and multiplied by 100 to enumerate percentages, based on microplate alamar 
blue assay (MABA) readings. Error bars represent standard deviations and were derived from three technical 
replicates.  
We speculated that the extent of gene repression might depend on the inoculum used 
in setting up the microdilution assay; that is, the total number of cells applied in each well of 
the microwell plate. This was investigated by monitoring the growth of liquid cultures at 
starting inoculums of 0.004, 0.016, 0.06 and 0.25 in the absence and presence of ATc. At the 
starting inoculum of 0.004, the growth of MSM_RibF was reduced by 11-fold compared to 




the uninduced control. As the inoculum was increased from 0.016 to 0.06 and 0.25, growth 
was less effectively repressed. That is, an increase in the inoculum caused the growth 
inhibition to be reduced by 7-fold, 3-fold and 1-fold, respectively, compared to the ATc 
unexposed control (Figure 3.5). All inocula concentrations revealed statistical significance in 
growth repression at 21 and 24 hours, P < 0.0001.  
As expected, the MSM_Vector and MSM_WT control strains showed negligible 
differences in growth at all inoculum concentrations under induced and uninduced conditions. 
The repression of mmpL3 expression led to a 20-fold decrease in growth at the lowest 
inoculum. As the starting inocula were adjusted to 0.016, 0.06 and 0.25, growth inhibition 
was less effective, resulting in 18-fold, 6-fold and 2-fold reduction, respectively, compared to 
the untreated culture. Similarly, all tested inoculum concentrations showed robust statistical 
significant differences in growth inhibition as early as 15 hours until 24 hours at the high 
inocula starting cultures of 0.06 and 0.25. In addition, the lowest inoculum revealed abundant 
differences at 24 hours and at 18, 21 and 24 hours using a 0.016 inoculum culture, P < 0.0001 
(Figure 3.5). These results demonstrated that gene repression, judged as the greatest log fold 
difference between ATc treated and untreated at the lowest starting inoculum had the greatest 
impact on bacterial growth.  Consequently, a starting inoculum of 0.004 was utilized for all 






Figure 3.5: CRISPRi-dependent growth repression is inoculum dependent. Growth kinetics of MSM_RibF, 
MSM_Vector, MSM_MmpL3 and MSM_WT in 7H9-OADC medium with varying inoculum concentrations: 
0.004, 0.016, 0.06 and 0.25. Cells were incubated for 24 hours with optical density (OD600) measurements taken 
at 3 hour intervals. The solid lines represent no ATc addition whereas the dashed lines represent the addition of 
100 ng/ml ATc. The inset shows the growth at different starting inocula in the first 12 hours. Each colour 
corresponds to a specific inoculum concentration and the data represent standard deviations (SDs) of 3 
biological replicates. Statistical comparisons were performed using Sidak’s multiple comparison test using a 
2way ANOVA multiple comparison analysis. 
We next determined the minimum inhibitory concentration of ATc (ATc “MIC”) 
required to induce effective transcriptional knockdown; i.e. that which manifested as above 

























































a starting OD600nm of 0.004 and exposed to serial 2-fold dilutions of ATc starting from 0.1-
100 ng/ml, and OD600nm readings were recorded at 3 hourly intervals for 24 hours (Figure 
3.6). The results demonstrated that MSM_RibF required a minimum of 18 hours for growth 
inhibition to become evident (this observation is consistent with other CRISPRi-mediated 
essential gene knockdowns in Msm; (de Wet et al. 2018) and that 3.125 ng/ml ATc 
represented the lowest concentration required to induce significant growth repression, P < 
0.0001. Overall, all ATc concentrations above 3.125 ng/ml were sufficient to mediate 
knockdown equivalent to exposure to 100 ng/ml ATc, whereas those below 3.125 ng/ml were 
less efficient in inducing knockdown (Figure 3.6).  
As expected, MSM_Vector and MSM_WT exhibited no significant differences in growth 
from 0 till 18 hour time points. However, unexpected significant differences were observed 
between the uninduced and ATc exposed MSM_Vector strains at 21 and 24 hours after 
exposure to 100, 50, 25, 12.5 and 6.3 ng/ml ATc concentrations, P < 0.0001, with no 
observable significance in MSM_WT at any time point (Figure 3.6). It is possible that the 
slight reduction in growth of this strain in the presence of ATc at 21 and 24 hours can be 
attributed to prolonged incubation with ATc which has been shown to affect the electron 
transport chain (Moullan et al. 2015). Further work is required to demonstrate this 
unequivocally. The growth of both MSM_MmpL3 and MSM_RibF were unaffected from 0 
till 15 hours, consistent with the inferred time lag required for the cell to exhaust the target 
proteins as a result of protein utilization or degradation. This suggests that a number of 
factors (including mRNA and protein turnover rates) likely determine how quickly a growth 
phenotype is detectable. MSM_MmpL3 growth was also reduced significantly in the 
presence of 3.125 ng/ml ATc at 21 and 24 hours, P < 0.0001 (Figure 3.6). Therefore, it 
appears that, in this system, more than 3.125 ng/ml ATc is required for full transcriptional 































































Figure 3.6: CRISPRi efficacy is ATc concentration dependent. Growth kinetics of MSM_RibF, 
MSM_Vector, MSM_MmpL3 and MSM_WT in 7H9 media. Cultures were started from an initial inoculum of 
an OD600nm of 0.004 and readings were taken at 3 hour time intervals over 24 hours. Coloured lines represent the 
different concentrations of ATc used ranging from 100 to 0 ng/ml. Data are representative of 3 biological 
replicates with SDs shown as error bars. Statistical analysis was conducted using the Dunnett’s multiple 
comparison test using a 2way ANOVA  analysis test.  
It was noteworthy that the ATc MIC of 3.125 ng/ml inferred from OD readings 
(Figure 3.6) to some degree varied from the MIC of 0.4-0.8 ng/ml suggested by fluorescence 
readings (Figure 3.4) in the sgRNA efficacy comparison. It seemed likely that this difference 
could be ascribed to the fact that the two assays employed different growth parameters of 
stationary growth in microtitre plate assay versus aerobic culturing in the flask. Previous 
observations also indicate that optical density does not necessarily directly correspond to 
viable fluorescence output (Arora et al. 2014).  
3.3 Consequence of ribF depletion on cell growth and viability in Msm  
Next, we determined the effect of ribF depletion on the growth and viability of the 
MSM_RibF strain by measuring optical density and CFUs during liquid culture. An adverse 
effect on bacterial growth could be detected as early as 12-15 hours post ATc induction 
(Figure 3.7). As expected, repression of ribF resulted in a 10-fold difference in growth at 24 
hours between the ATc-induced and uninduced strains. In addition, the corresponding CFU 
counts at this timepoint reflected no reduction in CFUs, indicating that ribF is essential for 
bacterial growth and that its depletion results in bacteriostasis. Furthermore, different colony 
morphotypes of RibF were observed from the ATc induced culture after plating 
(Supplementary figure S6). Noticeably, large colonies similar to MSM_WT were observed, 
however a smaller colony phenotype was also evident. Individual colonies were isolated and 
the genomic DNA extracted as outlined in 2.1.10. These samples were sent for whole genome 
sequencing analysis to identify the genetic basis for the observed colony morphologies; 
however results of this analysis are still pending. MSM_Vector and MSM_WT controls 
exhibited no observable impairment of bacterial growth in induced and uninduced cultures, 
indicating that the vector backbone alone had no effect on bacterial growth and no gene in the 
MSM_Vector strain was non-specifically targeted.  
The repression of mmpL3 resulted in a robust 20-fold reduction in growth in liquid 
media when induced with ATc and a subsequent 2.5 log-fold drop in CFUs at 24 hours, 




as has been previously demonstrated (Degiacomi et al. 2017), a minimal time of just 3 hours 
was sufficient to detect a reduction in CFUs indicating cell vulnerability as a consequence of 




























































Figure 3.7: CRISPRi mediates inducible knockdown of essential genes in Msm with measurable 
consequences on growth viability. (A) Growth curves and (B) corresponding CFU counts of MSM_RibF, 
MSM_Vector, MSM_MmpL3 and MSM_WT exposed to 0 (black line/triangle) or 100 ng/ml ATc (red 
line/square) for 24 hours. OD readings were taken every 3 hours and aliquots plated for CFU determination. 
Plotted lines represent OD readings while triangles and squares are CFU/ml counts. Error bars represent 
standard deviations of 3 biological replicates and the limit of detection is 10
2
 CFU/ml. 
3.4 Transcriptional downregulation of ribF by CRISPRi induction in Msm 
To confirm that the observed phenotypes could be equated to downregulation of ribF and 
were not a consequence of an off-target effect (Kim et al. 2015), the transcript levels of ribF 
were measured. Cultures were inoculated at an initial OD600nm of 0.016 into 7H9-OADC 
liquid medium. This inoculum concentration was chosen primarily to induce efficient 
knockdown while allowing for sufficient biomass for RNA extraction. RNA was extracted 
from induced and uninduced cultures at 24 hours. Synthesis of cDNA and qRT-PCR analysis 
was performed as detailed in 2.1.7. The results indicated effective knockdown in the induced 




MSM_MmpL3 revealed a 14-fold drop in transcript levels and similarly, there was a 11-fold 
reduction in transcript levels in MSM_RibF, P < 0.0001 (Figure 3.8). 
 
Figure 3.8: CRISPRi-mediated transcriptional depletion of mmpL3 and ribF. Black bars represent 
transcripts measured in strains grown in the absence of ATc (-ATc) while red bars indicate transcript levels in 
the presence of the inducer (+ATc). Error bars are SD of 3 technical replicates. Statistical analysis was 
conducted using Sidak’s multiple comparison in a 2way ANOVA multiple comparison analysis test. 
 
3.5 MSM_RibF lethality cannot be rescued by riboflavin, FMN or FAD 
The possibility that host-derived metabolites might rescue antibiotic-mediated nutrient 
auxotrophy is a key concern in targeting metabolic pathways for new TB drug development. 
For this reason, we tested the potential for uptake and assimilation of exogenous riboflavin 
(RF), FMN or FAD to rescue ribF depletion. To this end, the hypomorph strains were grown 
in 7H9-OADC medium to exponential phase before exposure to ATc (50 ng/ml) in 
combination with decreasing concentrations of each of the three potential metabolites of 
riboflavin biosynthesis: RF, FMN, or FAD (column 2 to 12). In this assay, the ability of each 
substrate to mitigate ribF depletion would result in improved growth relative to the 




inhibit growth (Figure 3.9, column 1), establishing that none was toxic at the concentrations 
applied. However, there was complete absence of growth in ATc-exposed cultures 
irrespective of the metabolite concentration provided, apparently eliminating the capacity in 
Msm for salvage or assimilation of these metabolites when RibF was depleted (Figure 3.9). 
As expected, MSM_Vector and MSM_WT were unaffected in all conditions and moreover, 
MSM_MmpL3 was not rescued by any of the additives. 
To validate these results, an equivalent spotting assay was performed. Briefly, 
cultures were grown to exponential phase in 7H9 and diluted serially in 2-fold increments 
prior to being spotted onto solid 7H10 medium containing any of the three metabolites alone 
or in combination with 100 ng/ml ATc. Again, the phenotypes observed, verified that none of 

































Figure 3.9: RF metabolites cannot rescue ribF depletion. Broth microdilution assays comprising 2-fold serial 
dilutions of each substrate with growth measured in relative fluorescence percentage. The concentrations of each 
substrate including the constant 50 ng/ml ATc are stipulated above each graph. Solid bars represent wells 
without ATc (-ATc) and patterned bars represent wells containing substrate with constant ATc (50 ng/ml) 






3.6 Comparison of the mycobacterial and human RibF protein 
The fact that ribF depletion could not be rescued by any of the tested metabolites (which are 
likely present in the human host) supported the notion that RibF could serve as an attractive 
target for new TB drug development. To determine the potential for selectivity, the 
mycobacterial RibF and its human RibF homolog structures were predicted using a protein 
computational modelling publicly available database; 
 
Protein Homology/analogY 
Recognition Engine version 2 (Phyre
2
). Full details of its use are provided in 2.1.11.3. 
Despite the inability of humans and other mammals to synthesize RF, humans do possess a 
RibF homolog which is required to convert RF acquired from the diet to the essential 
derivative cofactors. In contrast to most bacteria, the human homolog is not bifunctional and 
humans instead possess separate RF flavokinase (RFK/FMN1) and FAD synthetase (FLAD1) 
proteins (Brizio et al. 2006; Barile et al. 2000). 
Mtb RibF was used as the scaffold protein to model Msm RibF since the intention was 
to use this work to lay a foundation for follow-up investigations in the human pathogen. At 
both primary and tertiary levels, the Msm and Mtb proteins retained high sequence and 
structural similarity. Hence, the Mtb RibF protein scaffold was used to superimpose both the 
RFK and FLAD1 human proteins. These analyses indicated significant overlap between the 
Mtb RibF flavokinase and human flavokinase domains. In contrast, the FAD synthetase 
domains were non-homologous (Figure 3.10), suggesting that the FAD synthetase domain of 
the Mtb RibF protein should be preferentially targeted owing to the reduced risk of affecting 
the human FLAD1 protein.  
Numerous FAD synthetase inhibitors with different activities have been identified by 
(Sebastian et al. 2018) who optimised an activity-based high-throughput screening assay for 
compounds targeting Corynebacterium ammoniagenes FAD synthetase. The identified 
inhibitors include alexidine dihydrochloride, benzethonium chloride, thonzonium bromide 
and verteporfin. Favourable whole-cell antimicrobial properties of these inhibitors were also 
observed against Streptococcus pneumonia and Mtb (Sebastian et al. 2018). However, this 
does not necessarily validate the target since there is no evidence (in the absence of a 
hypomorph or resistant mutant) to confirm that the compound is actually interacting with the 
RibF protein. In principle, the compound could inhibit growth by an unrelated mechanism – a 




CRISPRi hypomorph provided a platform to validate if these compounds 





Figure 3.10: Structural homology between the Mtb and human RibF proteins. The red protein structure 
represents the Mtb RibF (A) whereas the yellow represents the Msm RibF (B). The blue represents the human 
RFK protein (C) and the green represents FLAD1, a FAD synthetase protein (D). Super-imposition of the Mtb 
RibF on the human RFK (E) and FLAD1 (F). All protein structures were adapted from Protein Homology/ 










3.7 Targeted depletion of ribF sensitizes Msm to putative FAD synthetase inhibitors and 
vancomycin 
Hypomorphs have proven very useful in demonstrating on-target efficacy of compounds 
designed to inhibit mycobacterial growth in whole-cell assays (Evans and Mizrahi 2015). To 
evaluate the susceptibility of the MSM_RibF mutant to putative FAD synthetase inhibitors – 
alexidine dihydrochloride (ADD), benzethonium chloride (BZC) and thonzonium bromide 
(TZB) – the microplate alamar blue assay (MABA) (Franzblau et al. 1998) was used to assess 
hypersensitivity, manifested by any shift in MIC as a consequence on ribF depletion. Several 
compounds with distinct mechanisms of action were also included to identify any increased 
susceptibility to known antimycobacterial agents, consequent on RF pathway disruption and 
include rifampicin, ethambutol, para- aminosalicylic acid (PAS) and vancomycin. In addition, 
riboswitch inhibitors ribocil-C and roseoflavin were also tested. 
First, the MIC of each compound was determined against MSM_WT to be used as a 
reference in order to establish if any shift in MICs that could be detected when testing 
MSM_RibF. Briefly, cultures were inoculated into 96-well microtitre plates, containing 
compounds diluted 2-fold and inhibition was determined colorimetrically via alamar blue 
reduction. The results demonstrated that MSM_WT was intrinsically resistant to roseoflavin, 
ribocil-C, verteporfin and para-aminosalicyclic acid (PAS), with MICs not determined at the 
concentrations used. In contrast, alexidine dihydrochloride, benzethonium chloride and 
thonzonium bromide returned weak MIC90 values of 80 µM, 12.5 µM, 25 µM, respectively 
except vancomycin which revealed an exceptionally low MIC90 of 0.0000055 µM, against 
MSM_WT (Table 3.2). MICs against known antimycobacterials was also determined (data 











Table 3.2: Minimal inhibitory concentrations and structures of proposed FAD 
synthetase inhibitors against Msm mc
2
155. 





























0.0000055 µM  
 
Standard checkerboard assays are used to investigate possible synergistic drug-drug 
combinations that exhibit increased bacterial inhibition at sub MIC concentrations (Bhusal, 
Shiohira, and Yamane 2005; Berenbaum 1978). The method was adapted here using ATc as a 
known “on target” partner drug in combination with the other Msm active compounds to 




Recent work from our lab (Omollo et al. 2019) demonstrated a synergistic interaction 
between chlorpromazine and spectinomycin and the set-up used in that study was applied 
here as a template to illustrate interpretation of the checkerboard data (Figure 3.11). So, each 
96 well plate was prepared such that column 1 and 12 represented “cell only” and “media 
only” controls, respectively. Row A represented drug X control with its specified MIC (light 
orange square (A5)) and similarly, well D2 (grey square) represented the MIC of drug Y in 
the drug Y control, column 2. The combination of the two drugs ranges from B3 diagonally 
to H11 (Figure 3.11). 
  
Figure 3.11: Evaluating synergistic interactions via checkerboard assay. Each square represents an 
individual well in a 96 well microtitre plate and representation of each borderline is listed under the legend on 
the right. The arrow points to the well that was used to calculate the fractional inhibitory concentration (FIC) 
index, where the two drugs inhibit more than 90% bacterial growth and elicited an FIC index (FICI) lower than 
0.5. This result is based on the resazurin assay, where the colour red indicates bacterial growth and pink 
represents bacterial inhibition.   
To calculate the FIC of drug X (FICdrugX), a well that represents more than 90% 
inhibition below the combinatorial MIC of both drugs was considered and was divided by the 
MIC of drug X alone. The same method was used to calculate the FIC of drugY (FICdrugY). 
To compute the fractional inhibitory concentration index (FICI), FICs of drugX and drugY 
were summed; ƩFICI= FICdrugX + FICdrugY. Using this approach, the checkerboard assay 
reveals 3 potential outcomes: synergistic, antagonistic, or no drug-drug interaction. For 
synergy, this is defined by the combinatorial ability of two drugs to produce greater bacterial 
inhibition than the sum of their individual effects and the ƩFICI must be below the threshold 









independently of each other, the ƩFICI lies between 0.5 and 4. Lastly, antagonism defines a 
combination of two compounds that are counter-effective, so that the ƩFICI is above 4 (Odds 
2003; Johnson et al. 2004). 
After determination of MICs for the tested compounds, checkerboard assays were 
performed with the aim of investigating the utility of the CRISPRi tool to validate compound 
mode of action and to test for any synergistic interactions as a consequence of RibF 
depletion. Checkerboard experiments demonstrated no interaction for TZC and ATc-treated 
MSM_RibF (Table 3.3). Both ADD and BZC revealed no well with more than 90% bacterial 
inhibition below the sub MICs and no FIC index could be calculated suggesting that they are 
likely targeting a different protein in an unrelated pathway; hence they do not show 
specificity to the tested RibF knockdowns. No interaction was defined by an FICI that is 
greater than 0.5 but less than or equal to 4. In addition, no antagonistic interaction was 
observed from all the tested combinations. Surprisingly, vancomycin, a cell wall targeting 
agent (Watanakunakorn 1984) displayed synergistic interaction with depletion of RibF 
(Figure 3.12) despite being unrelated to the RF pathway. However, these features were also 
manifested in the MSM_MmpL3 hypomorph, which had enhanced susceptibility to 
vancomycin and to the proposed FAD synthetase inhibitors and yet are not related to the 
mycolic acid biosynthesis pathway either (Supplementary figure S7). This suggests these 
inhibitors either have multiple modes of action and are not specifically targeting RibF or that 
the depletion of mmpL3 is increasing its susceptibility to these drugs as a consequence of an 













Table 3.3: In vitro additive interactions between ATc and selected FAD synthetase 



















































 a Compounds selected for checkerboard in vitro experiments are as follows; ADD, Alexidine dihydrochloride; 
BZC, Benzethonium chloride; TZB, Thonzonium bromide; VAN, Vancomycin and ATc, Anhydrotetracycline. 
b 
Minimum inhibitory concentration of each drug calculated as MIC90. The MIC used for ATc was MIC80.  
c 
Represented FICI values reflect the lowest values obtained from the 3 biological replicates; where synergy is 
classified by FICI ≤ 0.5, no interaction, as FICI > 0.5 t and ≤4 and antagonism as FICI > 4. 
Combinations that revealed synergistic interactions are highlighted in bold text and N/A represents absence of a 
well that exhibited more than 90% bacterial inhibition, hence the FIC of an individual compound and 























Figure 3.12: CRISPRi ribF knockdown strain demonstrates increased susceptibility to vancomycin and 
FAD synthetase inhibitors. A colour scale for percentage inhibition values is represented on the left (A), 
indicating maximal and minimal growth inhibition as pink (100%) and red (0), respectively. Standard 
checkerboard assays representing combinatorial data compiled in a 9 ATc x 7 drug matrix. Cells were treated 
with vancomycin and TZC against (B and D) ribF deficient and (C and E) WT control strains for 24 hours. The 
MICs for both ATc and VAN are represented in white ovals, with the well used to calculate the FICI indicated 
by a black circle.   
A control was used to compare the increased susceptibility to tested compounds 
following ribF depletion. As expected, MSM_WT revealed no increased susceptibility to any 
compound with no observable interaction (Figure 3.12 (C and E)). Experimental data of 




(Figure 3.12 (B and D) and (C and E)), and the additional tested compounds against 
MSM_MmpL3 and MSM_Vector are shown in supplementary figure S7. In addition, tested 
compound reliability was experimented by extending the standard checkerboard across two 
plates to ensure the integrity of the observed results (Supplementary figure S8).  
3.8 Regulatory role of RibF in Msm 
 
The flavin cofactor FMN has been shown to play a role in regulating the rib operon (ribDG-
E-AB-H) directly by influencing the “ribDG FMN riboswitch” located the 5’-UTR of the 
single transcription unit of ribDG-E-AB-H mRNA, precedent for which exists in B. subtilis 
but in contrast, RibR, a mycobacterial RibF homolog that has been shown to supersede 
repression by directly interacting with the aptamer region mediated by the FMN riboswitch 
(Solovieva et al. 1999; Higashitsuji et al. 2007; Pedrolli, Kuhm, et al. 2015). In E coli, 
however, the essential 3,4-dihydroxy-2-butanone-4-phosphate enzyme, RibB, has been 
shown to regulate the FMN riboswitch at both the transcriptional and translational levels 




Figure 3.13: Genomic context of the proposed RF operon in Msm. Green highlighted arrows represent RF 
genes, ribE, ribAB and ribH within the operon. The three arrows on the left of the operon are genes located 
upstream of the operon; those on the right are genes located downstream (adapted from Mycobrowser). 
 
To validate which genes constitute the rib operon, junction primers were used to 
amplify the region between two genes to confirm a single transcriptional unit. Results 




Unexpectedly, these results also indicated that the operon may extend beyond the RF 
biosynthesis genes into MSMEG_3074 and MSMEG_3075 (Figure 3.14). Whilst this 
suggests that ribE-ribAB-ribH-MSMEG_3074-MSMEG_3075 constitute a single 
transcriptional unit, this does not rule out the possibility of an overlapping transcriptional unit 
which may not span across the entire proposed rib operon and instead constitutes a subset of 




Figure 3.14: Confirmation of amplicons to determine the rib operon in Msm. The grey shaded arrows 
represent genes that are involved in RF biosynthesis while the non-shaded represent genes located upstream 
(left) and downstream (right) of the RF genes. Junction names between two genes are shown above each square 
bracket and RT represents presence (+RT) and absence (-RT) of reverse transcriptase. DNA represents presence 
of the template gDNA of Msm and the Molecular weight marker (Marker V) is shown on the left of 
electrophoresis gel image. 
 
The transcript levels of rib operon genes - ribE, ribAB and ribH - in the uninduced 
MSM_RibF strain were determined (Figure 3.13) by qRT-PCR and compared to the ribF 
depleted strain (Figure 3.15). The qRT-PCR reactions were performed using the procedure 
detailed in 2.1.7. The results demonstrated significant upregulation of rib operon genes, ribE 
and ribAB as a result of ribF depletion, P < 0.0233 and P < 0.0130 by 7-fold and 8-fold 
respectively. A 3-fold non-significant increase was observed for ribH (Figure 3.15). This 
strongly suggests that RibF could be a negative regulator of the operonic RF biosynthesis 
pathway genes. However, the exact mechanism of regulation still remains unknown; one 




protein binding to the upstream region of the regulatory elements of the RF operon. Further 
work is required to test these possibilities, and is complicated by the fact that the RibF protein 
and FMN metabolite are both limited in the ribF deficient strain.   
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Figure 3.15: Analysis of transcript levels of rib specific genes. Expression of indicated rib operon genes was 
determined in ATc induced (red bar) and uninduced (black bar) MSM_RibF cultures by qRT-PCR at 24 hours 
post CRISPRi induction from a 0.016 inoculum. Transcript levels were normalized to the ATc uninduced strain. 
Error bars represent SD of three technical replicates. Statistical analysis was performed using Sidak’s multiple 
comparison using a 2way ANOVA multiple comparison analysis. 
3.9 The effect of RibF depletion on RF metabolite levels 
We next sought to determine the effect of ribF transcriptional silencing on RF metabolite 
concentrations in the RibF deficient strain. To this end, cultures were inoculated to an initial 
OD600 of 0.016 in 7H9-OADC supplemented media containing either 0 or 100 ng/ml ATc. A 
crude extraction was performed using the procedure outlined in 2.1.9.7 prior to liquid 
chromatography mass spectrophotometry (LC-MS) analysis (Supplementary figure S9).  
Results revealed that there was a three times increase in the upstream substrate 6,7-




limit of quantification as was expected (Table 3.4) due to RibF being limited. The increase of 
DMRL could be attributed to the recycling route which converts one of the two DMRL 
molecules to 5-A-RU whilst the second molecule is converted to RF (Figure 3.16); however, 
this explains its enhanced abundance rather than the lack of RF substrate accumulation as 
would have been predicted to occur in the MSM_RibF hypomorph (Table 3.4). Furthermore, 
vitamin B12 synthesis is interconnected to RF biosynthesis, since an essential product from 
the RF pathway feeds into the vitamin B12 synthesis route. The substrate, 
dimethylbenzimidazole (DMB), is formed from reduced FMN (FMNH2) by the enzyme bluB 
(Figure 3.16). Hence it was expected that vitamin B12 synthesis would be restricted due to the 
scarcity in FMN intracellular concentrations emanating from the RF pathway in the RibF 
hypomorph.  
 
Figure 3.16: Biochemical reactions of RF metabolites carried out by RF enzymes. Enzymes that partake in 




solid line represents passive recycling of DMRL to 5-A-RU, both highlighted in purple rectangles. The blue 
rectangles represent the branch in the RF pathway to vitamin B12 synthesis surrounded by dotted lines.  
Table 3.4: Summary of RibF metabolite concentrations obtained after 24 hour post ATc 
exposure (+ATc) and in the absence of ATc (-ATc).  
Compound Strain: RibF 
 +ATc -ATc 
DMRL 14.44 4.22 





Vitamin B12 BLQ 0.081 

















































Newly approved TB drugs are being integrated into current and experimental TB drug 
regimens based on their novel metabolic targets and ability to inhibit both replicating and 
non-replicating bacilli (Barry, Boshoff, and Dowd 2004) (WHO 2008). These include 
bedaquiline, delamanid and pretonamid which respectively target essential elements such as 
the ATP synthase proton pump, synthesis of methoxy- and keto-mycolic acid and 
biosynthesis of mycobacterial mycolic acids (Andries, Verhasselt, Guillemont, Göhlmann, et 
al. 2005; Xavier and Lakshmanan 2014; Manjunatha, Boshoff, and Barry 2009). However, 
resistance to these drugs has already been documented and reiterates the need to identify new 
drug targets by excavating unexplored territory of Mtb metabolism (Somoskovi et al. 2015; 
Hartkoorn, Uplekar, and Cole 2014; Baptista et al. 2018). Riboflavin (RF) biosynthesis, an 
essential pathway in Mtb and plays a role in the generation of flavin cofactors; FMN and 
FAD which contribute to 25% and 75% of essential cellular reactions, respectively through  
flavoenzymes (Macheroux, Kappes, and Ealick 2011). Since these cofactors are uniquely 
generated in the RF pathway without any possibility of being compensated by other enzymes, 
they represent potentially useful drug targets.  
Interrogation of essential genes and their functions remains a priority as a means to 
identify possible drug targets. Conventional approaches to identify essential genes such as 
gene-deletion libraries (Baba et al. 2006; Winzeler et al. 1999) and saturating transposon 
mutagenesis (Goodman et al. 2009; Van Opijnen, Bodi, and Camilli 2009), cannot be used to 
characterize essential genes as, by definition, the cells do not survive in the absence of their 
essential functions and so are eliminated from libraries ab initio (Christen et al. 2011). 
However, new high-throughput tools have been developed to study essential genes namely 
destabilization of 3` UTR of mRNAs (DaMP alleles) (Breslow et al. 2008), CRISPR/Cas9 
gene editing (Blomen et al. 2015; Wang et al. 2015), and CRISPRi/dCas9 transcriptional 
interference (Gilbert et al. 2014).  
Here, we utilized a pioneering CRISPRi system optimized for mycobacteria (Rock et 
al. 2017). By evaluating several sgRNAs, we achieved inducible and dose-dependent 
transcriptional knockdown of ribF which varied depending on the sgRNA site within the 
target gene. As expected, sgRNAs that possessed the lower computationally calculated PAM 
scores elicited the most robust KD, while those with higher PAM scores showed reduced or 
partial KD (Figure 3.3 & 3.4) (Rock et al. 2017). This supports the potential tunability of the 
CRISPRi system by varying the PAM score selected (in turn, determining sgRNA-dCas9 




3.6) (Peters et al. 2016). Other studies have also shown that the strength of sgRNA-target 
gene complementarity can be adjusted by sgRNA target region shortening (Qi et al. 2013b), 
with optimal repression obtained with sgRNAs of 20 bp and lower repression mediated by 
shortening the sgRNA guide length to ~10 bp (Vigouroux et al. 2018).  
In bacteria, most bactericidal antibiotics exhibit potent bacterial killing when targeting 
actively growing cells, an effect which can be inoculum-dependent (Vandal et al. 2008). This 
is similar to what we have observed when CRISPRi strains at varying inoculum 
concentrations were challenged with a high ATc concentration of 100 ng/ml. Strikingly, the 
lowest inoculum concentration elicited the most potent transcriptional KD. This confirmed 
that the CRISPRi system is inoculum concentration dependent and its robustness relies on 
actively growing bacteria, preferably exponential phase cultures, while slow growing or 
stationary phase cultures seem to adversely affect the efficiency of the system by less-
effectively repressing growth (Figure 3.5).  
The notable bacterial growth cessation attained from moderate KD of ribF after 
approximately four generations (i.e. 12 hours) of growth suggests that, in Msm, these protein 
levels are not in excess in the cell. However, this is also dependent on the vulnerability of the 
functional target: targeting ribF led to a 10-fold reduction in growth whereas mmpL3 
depletion caused a greater than 20-fold reduction in bacterial growth in liquid media (Figure 
3.7). In addition, 12 hours and 3 hours were identified as the minimal time required for the 
CRISPRi inducer to significantly affect growth as a consequence of ribF or mmpL3 
depletion, respectively (Figure 3.7). This suggests that a number of factors (including mRNA 
and protein turnover rates) likely determine how quickly a growth phenotype is detectable. 
MmpL3 in particular serves as an essential membrane protein required for the transportation 
of trehalose mono-mycolates across the inner membrane (Xu et al. 2017b), the disruption of 
which renders the bacillus susceptible to external factors. 
It has also been shown that even where reduction in the levels of essential proteins 
such as dihydrofolate reductase (DHFR) and alanine racemase (alr) exceeds 97%, there 
might be no effect on mycobacterial growth and viability (Wei et al. 2011; Rock et al. 2017). 
This suggests that, in these cases, the amount of enzyme present was still adequate to fulfil its 
function without impeding growth (Wei et al. 2011). The results presented here indicate that 
RibF is a highly vulnerable target in mycobacteria, and possibly other pathogens with the 




The potential of the organism to scavenge essential nutrients can mitigate the lethality 
of antibiotic-mediated disruption of a targeted enzyme, ending the development aspirations of 
promising lead candidates (Brinster et al. 2009). This phenomenon was most clearly observed 
in Mtb, where toxicity mediated by GuaB2 depletion through VCC234718 drug treatment 
was rescuable by guanine (Singh et al. 2017). Highly efficient RF transporters have been 
identified in both Gram negative and Gram positive pathogenic bacteria, including S. aureus, 
E. faecalis, S. pyogenes and Vibrio cholera, all of which  are unable to synthesize RF de novo 
(Sepúlveda Cisternas, Salazar, and García-Angulo 2018; Deka et al. 2013; Wang et al. 2017). 
Moreover, it has been shown  that human serum contains enough RF to resuscitate a S. 
aureus RF auxotroph (Wang et al. 2017). To evaluate the possibility that mycobacteria might 
scavenge RF, we showed that genetic KD of ribF was not chemically complementable by the 
addition of RF, FMN and FAD (Figure 3.9; Supplementary figure S5). In contrast, in 
parallel work in our laboratory (Chengalroyen MD, personal communication), it has also 
been observed that a Mtb and Msm ribAB hypomorph – in which the first step of the RF 
pathway is silenced – are capable of rescue by exogenous RF, albeit at 43 µM and 11 µM 
respective RF concentrations, strongly supporting the capacity of the bacilli to assimilate 
exogenous RF. In turn, this observation supports the requirement for a functional RibF 
enzyme to enable conversion of RF to active flavin cofactors for use by flavoenzymes.  
The inability of FMN and FAD to complement ribF depletion indicates that the 
notoriously complex, hydrophobic mycobacterial cell wall is impermeable to these 
phosphate-containing nucleotides. Another possibility could be the inability of mycobacteria 
to utilize the cofactors to synthesize RF through a reverse reaction, evidence for which exists 
in bacteria such as Shewenella oneidensis, C. albicans and Pseudomonas aeruginosa. To our 
knowledge, no FMN nor FAD transporter has been identified in mycobacteria despite the 
conclusion from  a genomic analysis of Mtb that phosphate importers are overly represented 
in comparison to model bacteria, E. coli and B. subtilis (Braibant, Gilot, and Content 2000b). 
Notably, it has been observed that the exporter-to-importer proteins ratio is distinctly higher 
in Mtb than E.coli (Braibant, Gilot, and Content 2000a) which may be another reason for the 
reduction in small molecule uptake. 
The predicted tertiary structure of the bifunctional Mtb RibF protein was compared to 
the human homologs, RFK (flavokinase) and FLAD1 (FAD synthetase). This was done to 
determine the likelihood that drugs interacting with the Mtb RibF might also adversely affect 




of the human flavokinase, RFK, demonstrated that the structures were almost identical; in 
contrast, no structural homology with the human FAD synthetase was observed (Figure 
3.10). This strongly suggests that the FAD synthetase domain of Mtb RibF can be targeted 
without affecting the human homolog. In fact, the structural and biochemical distinctness of 
the mammalian FAD synthetases compared to the prokaryotic FAD synthetase is widely 
documented (Barile et al. 1993; Serrano et al. 2012; Efimov et al. 1998; Mack, van Loon, and 
Hohmann 1998b). Moreover, the availability of an array of bacterial FAD synthetase 
structures might expedite the development and design of both inhibitory compounds and 
activity assays (Herguedas et al. 2009; Wang et al. 2005; Wang et al. 2003). Bacterial FAD 
synthetases can be perceived as promising antimicrobial drug targets since interruptions in 
the production of FMN and FAD interfere with all pathways that involve flavoproteins and 
biosynthesis of these cofactors in most bacteria is facilitated by a single bifunctional enzyme, 
simultaneously disrupting both processes (Sassetti, Boyd, and Rubin 2003b; Griffin et al. 
2011b). The fundamental criteria for a good drug candidate stems from; (i) the essentiality of 
the target gene, (ii) the absence of off-target effects, iii) no opportunity for rescue by 
exogenous nutrient scavenging, and (iv) selective differences between the mammalian and 
bacterial target enzymes (Finberg et al. 2004; Copeland, Pompliano, and Meek 2006; Singh et 
al. 2017; Serrano et al. 2012). RibF appears to satisfy these criteria. 
The putative FAD synthetase inhibitors (Sebastián et al. 2018) exhibited no 
synergistic activity when used in combination with ribF depletion. This suggests that they 
either target a different protein in an unrelated pathway or have multiple modes of action 
(MOA) and target RibF in addition to other enzymes. The synergistic interaction observed 
with the RibF hypomorph and vancomycin was unanticipated (Figure 3.12) owing to the 
conventional MOA of vancomycin as a cell wall-targeting inhibitor. This suggests that the 
depletion of RibF led to bacterial cell wall impairment in turn leading to increased 
susceptibility to the cell wall targeting agent or that VAN weakens the cell wall to allow more 
ATc influx. Notably, this was not observed when the hypomorph was tested with ethambutol, 
also a cell wall targeting antibiotic (data not shown). At a practical level, it is worth noting 
that the checkerboard approach adopted in this study allowed for a rapid and more 
comprehensive validation of on-target activity and compound MOA determination across a 9 
by 7 compound concentration matrix as opposed to using a narrow 3 by 1 drug concentration 




In bacteria, RF homeostasis is mediated by FMN riboswitches, one of the 
predominate classes of RNA regulatory elements (Gutiérrez-Preciado et al. 2015) which 
controls gene expression required for the synthesis and transport of this vitamin (Winkler, 
Cohen-Chalamish, and Breaker 2002b; Gelfand et al. 1999; Mack, van Loon, and Hohmann 
1998b; Vitreschak et al. 2002b; Serganov, Huang, and Patel 2009; Pedrolli, Langer, et al. 
2015b). Our observations strongly support the notion that RibF is a negative regulator of the 
rib operon which comprises three RF biosynthesis related genes - ribE, ribAB, ribH - and 
MSMEG_3074 and MSMEG_3075. MSMEG_3074 is a conserved hypothetical protein while 
MSMEG_3075 codes for an acetyltransferase, Gcn5-related N-acetyltransferases (GNAT) 
family protein; neither appears to function in the RF pathway (Figure 3.13). However, the 
total length to which the Msm operon extends and the regulatory mechanism is still unknown. 
Regulation of the RF genes can be affected either by riboswitches or regulatory promoter 
elements. It is known that, in B. subtilis, both negative and positive regulation exists through 
FMN and RibR, respectively. FMN negatively regulates the rib operon by binding to the 
aptamer region domain which reduces the formation of FMN. In contrast, RibR has the 
ability to counteract this effect by binding to the FMN riboswitch to allow upregulation of the 
genes. In a similar manner, the expression of ribB is mediated by a FMN riboswitch in E. coli 
but retains a bifunctional role, working at both the transcriptional and translational level 
(Pedrolli, Langer, et al. 2015a). Notably, Msm was completely resistant to FMN riboswitch 
inhibitors, ribocil-C and roseoflavin (Table 3.2), hence it is tempting to speculate that FMN 












In this study, the utility of CRISPRi allowed for the rapid validation of target gene 
essentiality. This system was also used to characterize the effect of disrupting an essential 
gene by monitoring its effect on mycobacterial growth and evaluating the on-target activity of 
proposed inhibitors. It was demonstrated that the depletion of RibF was bacteriostatic, the 
nature of which was linked to a reduction in flavin cofactors. In addition, the adverse effect 
on the vitamin B12 biosynthesis pathway indicated that routes which rely on these essential 
cofactors are also affected. In accordance with this, RibF depletion led to enhanced 
susceptibility to vancomycin which we speculate could be attributed to the disruption of the 
activity of flavoproteins involved in cell wall biosynthesis such as DprE1 and DprE2 for 
which future prospects are to test against DprE1 inhibitors, most notably benzothiazinones 
(BTZ) (Makarov et al. 2015).  Preliminary data in the laboratory strongly supports the 
existence of a RF transporter. However, neither RF, FMN nor FAD supplementation had the 
ability to rescue this lethal phenotype. These favourable attributes led to the evaluation of 
proposed FAD synthetase inhibitors to target RibF. However, the compounds tested revealed 
either an off-target effect or possible multiple action against RibF and a secondary target/ 
cellular processes. Nevertheless, this work has demonstrated a non-redundant and essential 
role for RibF in mycobacterial metabolism, making it an attractive drug target to investigate 
in the future. Silencing ribF also led to the upregulation of the rib operon providing strong 





Figure 4.1: Consequence of RibF depletion in Msm. RF biosynthesis under normal conditions (left) and 
phenotypic and metabolite alterations resulting from RibF depletion (right). DMRL, 6,7-dimethyl-8-
ribityllumazine; FAD, Flavin adenine dinucleotide; FMN, Flavin mononucleotide; Msm, Mycobacterium 






Recent studies describe a pivotal role of MAIT cells in controlling TB progression (Le 
Bourhis et al. 2010; Gold et al. 2010; Kurioka et al. 2015). These cells are regarded as 
bridging cells that participate both in the innate and adaptive immunity. Like innate cells, 
they serve as the first line of defence against bacterial intruders yet like adaptive immune 
cells they are able to acquire effector memory. The most distinguishing feature comes from 
their unique ability to recognize pathogen derived RF metabolites presented by antigen 
presenting cells (APC) via an MR1 protein. The use of CRISPRi provided a platform to 
reduce the RibF enzyme, causing the accumulation of a specified RF precursor, 6,7-dimethyl-
8-ribityllumazine (DMRL) which is  associated with the ability to stimulate MAIT cell 
activity (Corbett et al. 2014). In the wider scope of this project, our collaborator Prof. David 
Lewinsohn and his research group at the Oregon Health & Science University (specialists in 
MAIT cell research) propose to comprehensively characterize immunological responses in 
relation to the RibF hypomorph generated in this study with the potential to provide insight 
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Table 1: List of genes predicted to participate in RF biosynthesis. The genes in green represent rib genes from 























Figure S1: Genomic contexts of ribF in Msm, Mtb, M. leprae, E. coli and; ribC and ribR representative of ribF 



















Figure S2: Genomic contexts of all remaining (MSMEG_3067, 2800 and 6053) and duplicate (MSMEG_5219, 
2787) genes that participate the RF biosynthetic pathway and gene products they encode in Mycobacterium 

























Figure S3: Illustration of nucleotide sequence homology between ribF in Msm, Mtb, M. leprae, E. coli and B. 






























Figure S5: MSM_RibF lethality cannot be rescued by riboflavin, FMN and FAD. Spotting assays of 
exponential phase cultures in 2-fold dilutions on standard 7H10 medium without ATc plus substrate (-
ATc/+substrate) (Left) and with ATc plus substrate (+ATc/+substrate) (Right). Strain names are indicated on 
the left of the images. Results represent one of the three biological replicates. The first spot in each case contains 










Figure S6: Images of colony morphologies observed post-5-day incubation.  Bacterial cultures were plated 
on 7H10/OADC supplemented agar prior to non-ATc (-ATc) and ATc (+ATc) induction for a period of 24 















Figure S7: CRISPRi mmpL3 knockdown strain demonstrates increased susceptibility to vancomycin and 
FAD synthetase inhibitors; ADD and TZC. Standard checkerboard assays representing combinatorial data 
compiled in a 9 ATc x 7 drug matrix. Cells were treated with ADD, BZC, TZB and VAN against ribF (A and 
B), mmpL3 (E, F, G and H) deficient, WT (C and D) and Vector (I, J, K and L) control strains for 24 hours. 
The MICs for both ATc and tested drugs are represented in white ovals, with the well used to calculate the FICI 









Figure S8: Standard checkerboard assays representing combinatorial data compiled in a 18 ATc x 7 drug matrix 
(2 x 96 well-microtiter plates). Cells were treated with TZB and VAN against ribF (A and B) and mmpL3 (C 




























Figure S9: LC-MS analytical standard traces of each of the compounds. Results reflect the concentration, 





Table 1: Different media used in this study and their compositions  
Media name Composition 
Luria-Bertani Broth 10 g tryptone 
10 g NaCl 
5 g yeast extract  
Luria-Bertani Agar 10 g tryptone 
10 g NaCl 
5 g yeast extract 
15 g bacteriological agar 
2 x TY 4 g NaCl  
10 g yeast extract 
16 g tryptone 




2 ml glycerol (Merck, Germany) 
2 ml 25% Tween 80 
100 ml OADC Middelbrook OADC 
Enchrichment (BD Microbiology Systems, 
USA) 




5 ml glycerol (Merck, Germany) 
100 ml OADC Middelbrook OADC 













Figure 2: Gel electrophoresis images of DNA Molecular weight marker III (left) and V (right). 
 
 
